Aurinia Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Aurinia Pharmaceuticals Inc together

Penke I guess you are interested in Aurinia Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Aurinia Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Aurinia Pharmaceuticals Inc

I send you an email if I find something interesting about Aurinia Pharmaceuticals Inc.

Quick analysis of Aurinia Pharmaceuticals Inc (30 sec.)

What can you expect buying and holding a share of Aurinia Pharmaceuticals Inc? (30 sec.)

How much money do you get?

$0.00

When do you have the money?

1 year

How often do you get paid?

0.0%

What is your share worth?

Current worth

$2.61

Expected worth in 1 year

$2.42

How sure are you?

32.5%

+ What do you gain per year?

Total Gains per Share

$-0.19

Return On Investment

-3.8%

For what price can you sell your share?

Current Price per Share

$5.03

Expected price per share

$4.07 - $6.9401

How sure are you?

50%

1. Valuation of Aurinia Pharmaceuticals Inc (5 min.)

Live pricePrice per Share (EOD)

$5.03

Book Value per Share

$2.61

Intrinsic Value Per Share

$-3.06 - $2.00

Total Value Per Share

$-0.45 - $4.61

My calculation of the intrinsic value of Aurinia Pharmaceuticals Inc is based how much money is coming from the company's main activities (Free Cash Flow).

The following numbers are based on moving averages and per share and per quarter.
I use a 6% discount rate for the low estimation and 3% for the high estimation.
The current Free Cash Flow Per Share is 10Y: ($-0.10) 3Y: ($-0.16) TTM: ($-0.06)
The change per quarter (trend) of the Free Cash Flow Per Share is 10Y: ($0.00) 3Y: ($0.01) TTM: ($0.01)

Years	Total Low est.	Total High est.	Added Free Cash Flow
1	$-0.58	$-0.30	$-0.58 - $-0.26
2	$-1.08	$-0.48	$-0.53 - $-0.13
3	$-1.51	$-0.53	$-0.48 - $-0.01
4	$-1.88	$-0.46	$-0.44 - $0.12
5	$-2.19	$-0.29	$-0.39 - $0.25
6	$-2.45	$-0.01	$-0.34 - $0.37
7	$-2.66	$0.36	$-0.29 - $0.50
8	$-2.83	$0.82	$-0.25 - $0.63
9	$-2.96	$1.37	$-0.20 - $0.75
10	$-3.06	$2.00	$-0.15 - $0.88

2. Growth of Aurinia Pharmaceuticals Inc (5 min.)

Is Aurinia Pharmaceuticals Inc growing?

	Current year	Previous year	Grow	Grow %
How rich?	$377.9m	$425.1m	-$37m	-9.5%

How much money is Aurinia Pharmaceuticals Inc making?

	Current year	Previous year	Grow	Grow %
Making money	-$19.5m	-$27m	$7.5m	38.7%
Net Profit Margin	-47.0%	-101.9%	-	-

How much money comes from the company's main activities?

Quarterly Yearly

3. Financial Health of Aurinia Pharmaceuticals Inc (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

Richest
#149 / 1010

Most Revenue
#161 / 1010

Most Profit
#692 / 1010

Most Efficient
#527 / 1010

What can you expect buying and holding a share of Aurinia Pharmaceuticals Inc? (5 min.)

Welcome investor! Aurinia Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Aurinia Pharmaceuticals Inc.

What can you expect buying and holding a share of Aurinia Pharmaceuticals Inc?

First you should know what it really means to hold a share of Aurinia Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Aurinia Pharmaceuticals Inc is $5.03. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

The fundamentals: the financial health trends of Aurinia Pharmaceuticals Inc.
The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Aurinia Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.61. Based on the TTM, the Book Value Change Per Share is $-0.05 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.13 per quarter.
You may receive quarterly/yearly dividend in the form of additional shares.
You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.

Based on historical numbers we can estimate the returns while holding a share of Aurinia Pharmaceuticals Inc.

How much money are you going to get?

	MRQ		TTM		YOY		5Y		10Y
	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share
Usd Eps	-0.19	-3.7%	-0.13	-2.7%	-0.19	-3.7%	-0.21	-4.1%	-0.14	-2.8%
Usd Book Value Change Per Share	-0.10	-1.9%	-0.05	-0.9%	-0.13	-2.5%	0.09	1.8%	0.06	1.3%
Usd Dividend Per Share	0.00	0.0%	0.00	0.0%	0.00	0.0%	0.00	0.0%	0.00	0.0%
Usd Total Gains Per Share	-0.10	-1.9%	-0.05	-0.9%	-0.13	-2.5%	0.09	1.8%	0.06	1.3%
Usd Price Per Share	8.99	-	9.35	-	8.57	-	12.03	-	8.10	-
Price to Earnings Ratio	-12.09	-	-19.64	-	-14.59	-	-18.66	-	-17.92	-
Price-to-Total Gains Ratio	-93.38	-	-540.87	-	-830.71	-	-305.33	-	-145.54	-
Price to Book Ratio	3.44	-	3.48	-	2.88	-	5.66	-	8.62	-
Price-to-Total Gains Ratio	-93.38	-	-540.87	-	-830.71	-	-305.33	-	-145.54	-

When do you get the money?

Usd Investment	$.00
Usd Price Per Share	5.03
Number of shares	198

Gains per Quarter	Trailing 12 Months	5 Year
Usd Dividend Per Share	0.00	0.00
Usd Book Value Change Per Share	-0.05	0.09
Usd Total Gains Per Share	-0.05	0.09
Gains per Quarter (198 shares)	-9.41	18.17
Gains per Year (198 shares)	-37.62	72.67

Years	Return on Investment (TTM)			Return on Investment (5Y)
	Dividend	Book Value gain	Total gains	Dividend	Book Value gain	Total gains
Broker costs	-	-	-10	-	-	-10
1	0	-38	-48	0	73	63
2	0	-75	-86	0	145	136
3	0	-113	-124	0	218	209
4	0	-150	-162	0	291	282
5	0	-188	-200	0	363	355
6	0	-226	-238	0	436	428
7	0	-263	-276	0	509	501
8	0	-301	-314	0	581	574
9	0	-339	-352	0	654	647
10	0	-376	-390	0	727	720

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %

	Trailing 12 Months				3Y				5 Year				10 Year				ALLTIME
				%				%				%				%				%
Earnings Per Share	0.0	4.0	0.0	0.0%	0.0	12.0	0.0	0.0%	0.0	20.0	0.0	0.0%	2.0	38.0	0.0	5.0%	11.0	88.0	2.0	10.9%
Book Value Change Per Share	1.0	3.0	0.0	25.0%	2.0	10.0	0.0	16.7%	6.0	14.0	0.0	30.0%	13.0	27.0	0.0	32.5%	36.0	65.0	0.0	35.6%
Dividend per Share	0.0	0.0	4.0	0.0%	0.0	0.0	12.0	0.0%	0.0	0.0	20.0	0.0%	0.0	0.0	40.0	0.0%	0.0	0.0	101.0	0.0%
Total Gains per Share	1.0	3.0	0.0	25.0%	2.0	10.0	0.0	16.7%	6.0	14.0	0.0	30.0%	13.0	27.0	0.0	32.5%	36.0	65.0	0.0	35.6%

Fundamentals of Aurinia Pharmaceuticals Inc

About Aurinia Pharmaceuticals Inc

https://www.auriniapharma.com
Biotechnology
300
118 Avenue , 14315, Edmonton, AB, Canada, T5L 4S6
Google Maps Bing Maps

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Fundamental data was last updated by Penke on 2024-04-11 01:27:04.

Financial Health

Profitability Details

	Compared to previous year	Compared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.

Operating Efficiency Details

	Compared to previous year	Compared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.

Liquidity Details

	Compared to previous year	Compared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.

Solvency Details

	Compared to previous year	Compared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details

	Compared to previous year	Compared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Aurinia Pharmaceuticals Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Measures how much net profit Aurinia Pharmaceuticals Inc earns for each $1 of revenue.

Above 10% is considered healthy but always compare Aurinia Pharmaceuticals Inc to the Biotechnology industry mean.
A Net Profit Margin of -59.6% means that $-0.60 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Aurinia Pharmaceuticals Inc:

The MRQ is -59.6%. The company is making a huge loss. -2
The TTM is -47.0%. The company is making a huge loss. -2

Trends

Current period		Compared to		+/-
MRQ	-59.6%	TTM	-47.0%	-12.6%
TTM	-47.0%	YOY	-101.9%	+54.9%
TTM	-47.0%	5Y	-32,496.5%	+32,449.4%
5Y	-32,496.5%	10Y	-28,888.1%	-3,608.4%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-59.6%	-200.1%	+140.5%
TTM	-47.0%	-216.8%	+169.8%
YOY	-101.9%	-288.3%	+186.4%
5Y	-32,496.5%	-449.1%	-32,047.4%
10Y	-28,888.1%	-605.5%	-28,282.6%

Measures how much net profit Aurinia Pharmaceuticals Inc earns for each $1 of revenue.

Revenue is the amount of profit Aurinia Pharmaceuticals Inc generates before taxes and all other costs. For example, when you buy a cup of coffee it will cost you $3. The company does not earn $3 in profit but also has to pay various costs and taxes to create that cup of coffee. Let's assume the cost of creating a cup of coffee is $1.5.

The $3 you pay for a cup of coffee is called revenue.
The $1.5 that’s left over when all costs to create that cup of coffee (including taxes) are deduced from the revenue is called net profit.

The net profit margin looks at how much net profit Aurinia Pharmaceuticals Inc earns for each $1 in revenue.

How to use net profit margin

Higher profit margin is better (more profit).
Above 10% is considered healthy but always compare Aurinia Pharmaceuticals Inc to the Biotechnology industry mean.
Can be used to compare companies within the Biotechnology industry.

You typically want a high profit margin. This means that for each $1 in sales, Aurinia Pharmaceuticals Inc makes more profit. This shows the investor how efficiently Aurinia Pharmaceuticals Inc is operating in general and compared to other companies in the same industry. Aurinia Pharmaceuticals Inc operates in the Biotechnology industry.

Why do investors use net profit margin in their analysis

It helps investors to determine the efficiency of Aurinia Pharmaceuticals Inc. If profit margins remain low (compared to the Biotechnology industry mean) and there are no improvements to make in production costs or other areas that might be a warning sign. If profit margins are high that means the company has low overhead costs and is efficiently using its resources to generate profit.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Net Profit Margin of Aurinia Pharmaceuticals Inc is -0.60. This means that Aurinia Pharmaceuticals Inc earned $-0.60 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Net Profit Margin of the Biotechnology industry is -200.1%.
What is the trend?
The trend is important because it shows you how Aurinia Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Aurinia Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Aurinia Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare Aurinia Pharmaceuticals Inc with other companies in the same industry (Biotechnology).
Net profit margin should rise over the years.
Can be influenced when Aurinia Pharmaceuticals Inc sells assets (profit will increase while costs remain the same).
It won’t show what part of Aurinia Pharmaceuticals Inc is doing great or needs improvement (it only looks at total revenue and total net income).

How to calculate net profit margin

Net profit margin = net income / total revenue * 100%

Real example of Aurinia Pharmaceuticals Inc

You need the following data to determine net profit margin:

Income statement from the period you want to calculate (for example, MRQ or TTM).

Net income MRQ Aurinia Pharmaceuticals Inc = -26,875
Total revenue MRQ Aurinia Pharmaceuticals Inc = 45,095
$-26,875 / $45,095 = -0.60 or -59.6%

Higher is better

The higher the net profit margin, the more efficient the company is generating income. This helps investors to determine how the company is managing money. The net profit margin is an important indicator when diving into the financial health of a company. Overall, you want to see the net profit margin rising over the years. That means the company improved their production and made it more efficient (if possible).

You can use the net profit margin to compare companies within the same industry. If there are two companies where one is much bigger but the smaller one has a higher net profit margin, that means the smaller company is more efficiently using operational costs.

Important: Profit margins can be very different between industries. Companies with assembly lines or transports are much more prone to see shifting in prices for fuel, ingredients and maintenance compared to companies that only provide services. You should never compare net profit margin between different industries.

1.1.2. Return on Assets

Shows how efficient Aurinia Pharmaceuticals Inc is using its assets to generate profit.

Above 5% is considered healthy but always compare Aurinia Pharmaceuticals Inc to the Biotechnology industry mean.
-4.9% Return on Assets means that Aurinia Pharmaceuticals Inc generated $-0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Aurinia Pharmaceuticals Inc:

The MRQ is -4.9%. Using its assets, the company is very inefficient in making profit. -2
The TTM is -3.8%. Using its assets, the company is very inefficient in making profit. -2

Trends

Current period		Compared to		+/-
MRQ	-4.9%	TTM	-3.8%	-1.1%
TTM	-3.8%	YOY	-5.5%	+1.7%
TTM	-3.8%	5Y	-8.0%	+4.2%
5Y	-8.0%	10Y	-9.2%	+1.2%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-4.9%	-13.3%	+8.4%
TTM	-3.8%	-12.8%	+9.0%
YOY	-5.5%	-11.7%	+6.2%
5Y	-8.0%	-13.9%	+5.9%
10Y	-9.2%	-15.7%	+6.5%

Shows how efficient Aurinia Pharmaceuticals Inc is using its assets to generate profit.

For a farm, a tractor is considered an asset. The tractor helps ploughing the land making it possible to plant and harvest crops. But the tractor might be old and needing maintenance all the time reducing its efficiency. Return on assets indicates how effectively the farm is using the tractor (and other assets that help the core business) to plough the land.

How to use return on assets

Higher is better.
Above 5% is considered healthy but always compare Aurinia Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on assets in their analysis

Shows the investor how effectively Aurinia Pharmaceuticals Inc is using its resources to generate profit. If the return on assets (-4.9%) from Aurinia Pharmaceuticals Inc are higher than the Biotechnology mean (-13.3%) that means Aurinia Pharmaceuticals Inc is using its resources better than their competitors. If not, that means their competitors are more efficient in using their resources to generate profit.

An investor should always look at:

What is the current return on assets?
The current most recent quarter (MRQ) Return on Assets of Aurinia Pharmaceuticals Inc is -4.9%. This means the company generated $-0.05 for each $1 in assets.
How does it compare to the industry?
The mean MRQ Return on Assets of the Biotechnology industry is -13.3%.
What is the trend?
The trend is important because it shows you how Aurinia Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Aurinia Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Aurinia Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
If a company has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

How to calculate return on assets

Return on assets = net income / total assets * 100%

Real example Aurinia Pharmaceuticals Inc

You need the following data to determine return on assets (ROA):

Income statement
Balance sheet

Net income MRQ (income statement) from Aurinia Pharmaceuticals Inc = -26,875
Total assets MRQ (balance sheet) from Aurinia Pharmaceuticals Inc = 548,062
-26,875 / 548,062 = -0.05 or -4.9%

ROA is an important ratio as it will tell you how effectively Aurinia Pharmaceuticals Inc is using its resources to generate profits. Example:

Bob and Kristin both sell ice cream in the summer. They both have an ice cream truck. The truck Bob owes cost him $20.000 and the truck Kristin owes cost her $1500. Over the summer, Bob earned $2000 and Kristin earned $200. To calculate the return on assets:

Bob: $2000 / $20.000 * 100% = 10%
Kristin: $200 / $1500 * 100% = 13.3%

This tells you Bob’s company is more valuable but Kristin's company is more efficient. Be aware that total assets can change over time. A transportation business will buy and sell trucks or planes all the time. Before using return on assets as a guideline, you have to know what the exact assets are. For a company that has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

1.1.3. Return on Equity

Shows how efficient Aurinia Pharmaceuticals Inc is using its investors money to generate profit.

Above 15%-20% is considered healthy but always compare Aurinia Pharmaceuticals Inc to the Biotechnology industry mean.
-7.1% Return on Equity means Aurinia Pharmaceuticals Inc generated $-0.07 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Aurinia Pharmaceuticals Inc:

The MRQ is -7.1%. Using its investors money, the company is very inefficient in making profit. -2
The TTM is -5.0%. Using its investors money, the company is very inefficient in making profit. -2

Trends

Current period		Compared to		+/-
MRQ	-7.1%	TTM	-5.0%	-2.1%
TTM	-5.0%	YOY	-6.3%	+1.3%
TTM	-5.0%	5Y	-9.6%	+4.5%
5Y	-9.6%	10Y	-12.3%	+2.8%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-7.1%	-16.9%	+9.8%
TTM	-5.0%	-16.1%	+11.1%
YOY	-6.3%	-15.1%	+8.8%
5Y	-9.6%	-19.3%	+9.7%
10Y	-12.3%	-20.2%	+7.9%

Shows how efficient Aurinia Pharmaceuticals Inc is using its investors money to generate profit.

A publicly traded company (any company that issues shares to the public) is owned by its shareholders. Return on equity calculates the amount of profit for every $1 the shareholders invested.

How to use return on equity

Higher is better.
Above 15%-20% is considered healthy but always compare Aurinia Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on equity in their analysis

To find out the owners/management's attitude toward their company. You typically want the owners/management to invest in the company and focus on generating profit. If not enough profit is generated (compared to the Biotechnology industry mean), the company might not be investing their money efficiently.

The three steps every investor should look at:

What is the current return on equity?
The current most recent quarter (MRQ) Return on Equity of Aurinia Pharmaceuticals Inc is -7.1%. This means Aurinia Pharmaceuticals Inc generated $-0.07 for each $1 the owners (shareholders) invested.
How does it compare to the industry?
The mean MRQ Return on Equity of the Biotechnology industry is -16.9%.
What is the trend?
The trend is important because it shows you how Aurinia Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Aurinia Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Aurinia Pharmaceuticals Inc up to 10 years back (depending if Aurinia Pharmaceuticals Inc existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Does not include intangible assets (non physical assets like licences, computer software, etc.).
Stockholders equity and shareholders equity refer to the same thing.
Liabilities should not be more than three times return on equity.

How to calculate return on equity

Return on equity = net profit / shareholders equity * 100%

Real example of Aurinia Pharmaceuticals Inc

You need the following data to determine ROE:

Income statement
Balance sheet
Net profit MRQ (income statement) Aurinia Pharmaceuticals Inc = -26,875
Shareholders equity (balance sheet) MRQ Aurinia Pharmaceuticals Inc = 377,954
-26,875 / 377,954 = -0.07 or -7.1%

A negative shareholder equity is a warning sign. It means the company has more liabilities than assets. It might also mean that the owners did not invest enough money or they are taking money out of the business.

1.2. Operating Efficiency of Aurinia Pharmaceuticals Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Measures how efficient Aurinia Pharmaceuticals Inc is operating .

Measures how much profit Aurinia Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
Above 15% is considered healthy but always compare Aurinia Pharmaceuticals Inc to the Biotechnology industry mean.
An Operating Margin of -45.7% means the company generated $-0.46 for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Aurinia Pharmaceuticals Inc:

The MRQ is -45.7%. The company is operating very inefficient. -2
The TTM is -46.1%. The company is operating very inefficient. -2

Trends

Current period		Compared to		+/-
MRQ	-45.7%	TTM	-46.1%	+0.4%
TTM	-46.1%	YOY	-104.9%	+58.8%
TTM	-46.1%	5Y	-25,945.5%	+25,899.4%
5Y	-25,945.5%	10Y	-20,065.4%	-5,880.1%

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	-45.7%	-296.2%	+250.5%
TTM	-46.1%	-232.5%	+186.4%
YOY	-104.9%	-298.2%	+193.3%
5Y	-25,945.5%	-492.1%	-25,453.4%
10Y	-20,065.4%	-632.4%	-19,433.0%

Measures how efficient Aurinia Pharmaceuticals Inc is operating .

The more effecient a company creates products or provides services, the more profit it generates.

How to use operating margin

Higher is better
Above 15% is considered healthy but always compare Aurinia Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries
Can be used to compare companies

Why do investors use operating margin in their analysis

To determine how much profit Aurinia Pharmaceuticals Inc is making from it’s core business.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Operating Margin of Aurinia Pharmaceuticals Inc is -45.7%. This means that Aurinia Pharmaceuticals Inc earned $-0.46 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Margin of the Biotechnology industry is -296.2%.
What is the trend?
The trend is important because it shows you how Aurinia Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Aurinia Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Aurinia Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Can be calculated in different ways

How to calculate operating margin

Operating margin = operating earnings / total revenue

Real example of Aurinia Pharmaceuticals Inc

You need the following data to determine operating margin:

Income statement
Operating earnings MRQ Aurinia Pharmaceuticals Inc = -20,600
Total revenue MRQ Aurinia Pharmaceuticals Inc = 45,095
$-20,600 / $45,095 = -0.46 or -45.7%

Operating margin is used to calculate how much profit a company makes after variable costs of production but before paying interest and taxes. Some variable costs examples are wages, raw materials, packaging, and transaction fees. The amount of variable costs is different for each company and industry. In general, a higher operating margin is better as this implicates that a company is running efficiently.

For investors, a higher operating margin is a good sign. Although you should always look at operating margin in the long term. If operating margin is fluctuating over the years this might be a sign that things are not running efficiently enough. It’s a way to check how much profit a company is making from its core business.

Operation earnings can be calculated in multiple ways:

Operation earnings = EBIT - non operating income + non operating expense
Operation earnings = Gross profit - operating expense - depreciation and amortisation
Operation earnings = Total revenue - COGS (costs of goods sold) - indirect costs

1.2.2. Operating Ratio

Measures how efficient Aurinia Pharmaceuticals Inc is keeping operating costs low.

Below 1 is considered healthy (always compare to Biotechnology industry mean).
An Operation Ratio of 1.46 means that the operating costs are $1.46 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Aurinia Pharmaceuticals Inc:

The MRQ is 1.457. The company is inefficient in keeping operating costs low. -1
The TTM is 1.501. The company is inefficient in keeping operating costs low. -1

Trends

Current period		Compared to		+/-
MRQ	1.457	TTM	1.501	-0.044
TTM	1.501	YOY	2.047	-0.546
TTM	1.501	5Y	364.647	-363.146
5Y	364.647	10Y	325.936	+38.711

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	1.457	3.231	-1.774
TTM	1.501	3.310	-1.809
YOY	2.047	3.890	-1.843
5Y	364.647	5.739	+358.908
10Y	325.936	7.876	+318.060

Measures how efficient Aurinia Pharmaceuticals Inc is keeping operating costs low.

If the operating ratio is below 1 that means the company is making money. The lower the operating ratio, the more efficient the company.

How to use operating ratio

Lower is better.
Below 1 is considered healthy but always compare Aurinia Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use operating ratio in their analysis

Shows if costs of creating products and or services is increasing or decreasing. The lower the operating ratio, the more efficient the company is creating products and services.

The three steps every investor should look at:

What is the current Operatin ratio?
The current most recent quarter (MRQ) Operating Ratio of Aurinia Pharmaceuticals Inc is 145.7%. This means that Aurinia Pharmaceuticals Inc earned $1.46 for each $1 in net sales in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Ratio of the Biotechnology industry is 3.23.
What is the trend?
The trend is important because it shows you how Aurinia Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Aurinia Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Aurinia Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
You need COGS to calculate operating ratio which is not always shown in the income statement.
Does not consider debt.

How to calculate operating ratio

Operating ratio = Operating expenses + COGS \ Net sales

Real life example Aurinia Pharmaceuticals Inc

You need the following data to determine operating ratio:

Income statement

COGS is not always specified on the income statement. If so you can use the following calculation:

(cost of revenue + total operating expenses) \ total revenue
(5,395 +60,300) \ 45,095 = 1.46

The operating ratio measures the efficiency of a company at keeping low costs while generating profits from sales. It compares the total operating expenses to the net amount of sales. The total operating expenses exists of:

COGS (materials, labour, rent of facility, repairs)
Operating expenses (legal fees, marketing, wages, rent, maintenance/repairs)

Operating expenses are all the costs the company makes that are not directly tied to the production of the service or product. Where COGS are costs that are directly tied to the production of a product or service.

Do note that COGS is not always available in the income statement. Some companies include COGS in the operating expenses while others list COGS separately. To make it even more confusing, COGS is also known as “costs of sales” and costs of sales is the same as costs of revenue.

The operating ratio tells you how efficient the company is creating its products or services while keeping prices low. In this case, a lower ratio is better. Higher or rising operating ratios might tell you that costs are rising while sales are not improving or staying the same.

1.3. Liquidity of Aurinia Pharmaceuticals Inc.

1.3. Liquidity

1.3.1. Current Ratio

Measures if Aurinia Pharmaceuticals Inc is able to pay off Short-term Debt.

Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
A Current Ratio of 5.50 means the company has $5.50 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Aurinia Pharmaceuticals Inc:

The MRQ is 5.503. The company is very able to pay all its short-term debts. +2
The TTM is 7.024. The company is very able to pay all its short-term debts. +2

Trends

Current period		Compared to		+/-
MRQ	5.503	TTM	7.024	-1.521
TTM	7.024	YOY	11.952	-4.928
TTM	7.024	5Y	13.742	-6.718
5Y	13.742	10Y	14.748	-1.006

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	5.503	3.890	+1.613
TTM	7.024	4.173	+2.851
YOY	11.952	5.344	+6.608
5Y	13.742	6.126	+7.616
10Y	14.748	6.448	+8.300

Measures if Aurinia Pharmaceuticals Inc is able to pay off Short-term Debt.

How to use current ratio

Higher is better
Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
Can be very different between industries
Can be used to compare companies

Why do investors use current ratio in their analysis

Shows if the company can pay of short term debts if needed. A company that can't pay off it's short term debts might get in trouble if they have to pay off their short term debts for whatever reason. For example, markets can change due to global events like covid-19 or the war in Ukraine versus Russia. Because debts are always taken based on future income, it might become troublesome for Aurinia Pharmaceuticals Inc if something happens in the market that will cause sales to plummet.

The three steps every investor should look at:

What is the current current Ratio?
The current most recent quarter (MRQ) Current Ratio of Aurinia Pharmaceuticals Inc is 5.50. This means Aurinia Pharmaceuticals Inc has $5.50 in assets for each $1 in short-term debts.
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 3.89.
What is the trend?
The trend is important because it shows you how Aurinia Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Aurinia Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Aurinia Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Might be deluded.
Not all assets can always be quickly sold.
Can be manipulated by increasing or decreasing the assets and/or liabilities.

How to calculate current ratio

Current ratio = current assets \ current liabilities

Real life example Aurinia Pharmaceuticals Inc

You need the following data to determine operating ratio:

Balance sheet
Current ratio = current assets \ current liabilities
424,800 \ 77,188) = 5.50

The current ratio measures if Aurinia Pharmaceuticals Inc is able to pay short-term debts (obligations). Short term in this context means all debt obligations that are about to expire within one year. The current ratio incorporates current liabilities and current assets. Current assets are all the assets a company has that are expected to be consumed or sold within standard business operations. You can find the current assets in the balance sheet. They consist of:

Inventory
Accounts receivable
Marketable securities
Prepaid expenses
Cash
Cash equivalents
liquid assets

The current liabilities are short term obligations that are due within one year. These consist of:

Short term debts
Dividends
Income taxes
Short-term debts
Accounts payable
Interest payments

The result shows an investor if Aurinia Pharmaceuticals Inc is able to pay all its short-term debts if they were due all at once. When the result of the above formula is below 1, then Aurinia Pharmaceuticals Inc does not have enough capital after selling all its assets to pay all short-term debts. If the ratio drops far below 1 that might indicate Aurinia Pharmaceuticals Inc is or will be in financial trouble anytime soon.

Although this gives an investor some clues, the current ratio may also be deluded. Because owning assets does not mean the company can easily sell them. Also, Accounts receivable may be quite old (they will probably never pay) which deludes the current ratio. As with all ratios, you should only compare them between the same industries and companies.

1.3.2. Quick Ratio

Measures if Aurinia Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

Above 1 is considered healthy but always compare Aurinia Pharmaceuticals Inc to the Biotechnology industry mean.
A Quick Ratio of 8.76 means the company can pay off $8.76 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Aurinia Pharmaceuticals Inc:

The MRQ is 8.760. The company is very able to pay all its short-term debts with the most liquid assets. +2
The TTM is 10.923. The company is very able to pay all its short-term debts with the most liquid assets. +2

Trends

Current period		Compared to		+/-
MRQ	8.760	TTM	10.923	-2.163
TTM	10.923	YOY	18.081	-7.158
TTM	10.923	5Y	17.323	-6.400
5Y	17.323	10Y	17.709	-0.387

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	8.760	3.514	+5.246
TTM	10.923	3.998	+6.925
YOY	18.081	5.380	+12.701
5Y	17.323	6.105	+11.218
10Y	17.709	6.404	+11.305

Measures if Aurinia Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

How to use quick ratio

Higher is better.
Above 1 is considered healthy but always compare Aurinia Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use quick ratio in their analysis

Shows how fast Aurinia Pharmaceuticals Inc can pay off its short term debts. This shows if Aurinia Pharmaceuticals Inc can survive emergencies due to market changes or other reasons.

The three steps every investor should look at:

What is the current Quick Ratio?
The current most recent quarter (MRQ) quickRatio of Aurinia Pharmaceuticals Inc is 8.76. This means that Aurinia Pharmaceuticals Inc can pay off $8.76 for each $1 in debt (using most liquid assets).
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 3.51.
What is the trend?
The trend is important because it shows you how Aurinia Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Aurinia Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Aurinia Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Incorporates only most liquid assets.

How to calculate quick ratio

Quick ratio = cash and equivalents + marketable securities + accounts receivable / current liabilities

Real life example Aurinia Pharmaceuticals Inc

You need the following data to determine operating ratio:

Balance sheet
Quick ratio = cash and short-term investments + short-term investments + netReceivables / total current liabilities
MRQ quick ratio Aurinia Pharmaceuticals Inc: (350,489 + 301,614 +24,089) / 77,188 = 8.76

The quick ratio measures the same thing as the current ratio, only it uses the most liquid assets a company has. Meaning, the assets that can be sold for cash the easiest and fastest.

As the quick ratio only incorporates the most liquid assets, you should also check the current ratio which also includes less liquid assets. But they may be harder to sell.

1.4. Solvency of Aurinia Pharmaceuticals Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Measures how much % of Aurinia Pharmaceuticals Inc assets are financed with debt.

Below 1 (100%) is considered healthy but always compare Aurinia Pharmaceuticals Inc to Biotechnology industry mean.
A Debt to Asset Ratio of 0.31 means that Aurinia Pharmaceuticals Inc assets are financed with 31.0% credit (debt) and the remaining percentage (100% - 31.0%) is financed by its owners/shareholders.

Let's take a look of the Debt to Asset Ratio trends of Aurinia Pharmaceuticals Inc:

The MRQ is 0.310. The company is very able to pay all its debts by selling its assets. +2
The TTM is 0.256. The company is very able to pay all its debts by selling its assets. +2

Trends

Current period		Compared to		+/-
MRQ	0.310	TTM	0.256	+0.054
TTM	0.256	YOY	0.127	+0.129
TTM	0.256	5Y	0.168	+0.089
5Y	0.168	10Y	0.210	-0.043

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.310	0.339	-0.029
TTM	0.256	0.336	-0.080
YOY	0.127	0.271	-0.144
5Y	0.168	0.366	-0.198
10Y	0.210	0.389	-0.179

Measures how much % of Aurinia Pharmaceuticals Inc assets are financed with debt.

When there are more debts than assets, that means creditors have a larger stake Aurinia Pharmaceuticals Inc than its shareholders.

How to use debt to asset ratio

Lower is better.
below 1 (100%) is considered healthy but always compare Aurinia Pharmaceuticals Inc to Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to asset ratio in their analysis

It shows how much debt the company used to finance its assets. If a company is almost entirely financed with debt that means the company might get into serious trouble when emergencies arise like a raise in interest.

The three steps every investor should look at:

What is the current debt to asset ratio?
The current most recent quarter (MRQ) Debt to Asset Ratio of Aurinia Pharmaceuticals Inc is 0.31. This means means that Aurinia Pharmaceuticals Inc is financed with 31.0% credit and the remaining percentage is financed by it's owners (shareholders).
How does it compare to the industry?
The mean MRQ Current Ratio of the Biotechnology industry is 389.0%.
What is the trend?
The trend is important because it shows you how Aurinia Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Aurinia Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Aurinia Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Some companies can have higher debt to assets ratio's (for example, banks).
Debt to asset ratio should improve over the years.
If the debt to asset ratio is above 1, look at the industry mean and find out why Aurinia Pharmaceuticals Inc has so much debt.

How to calculate debt to asset ratio

Debt to asset ratio = total debt \ total assets

Real life example Aurinia Pharmaceuticals Inc

You need the following data to determine debt to asset ratio:

Balance sheet
Debt to asset ratio = total debt \ total assets
170,108 \ 548,062 = 31.0% or 0.31.

The debt to total assets ratio shows if the company is owned by creditors or shareholders. Or in other words, the total debt in relation to the total amount of assets. It shows how much debt the company used to finance its assets.

1.4.2. Debt to Equity Ratio

Measures if Aurinia Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

Below 2 is considered healthy but always compare Aurinia Pharmaceuticals Inc to the Biotechnology industry mean.
A Debt to Equity ratio of 45.0% means that company has $0.45 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Aurinia Pharmaceuticals Inc:

The MRQ is 0.450. The company is very able to pay all its debts with equity. +2
The TTM is 0.356. The company is very able to pay all its debts with equity. +2

Trends

Current period		Compared to		+/-
MRQ	0.450	TTM	0.356	+0.094
TTM	0.356	YOY	0.146	+0.210
TTM	0.356	5Y	0.208	+0.148
5Y	0.208	10Y	0.291	-0.083

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
MRQ	0.450	0.388	+0.062
TTM	0.356	0.402	-0.046
YOY	0.146	0.335	-0.189
5Y	0.208	0.426	-0.218
10Y	0.291	0.461	-0.170

Measures if Aurinia Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

How to use debt to equity ratio

Lower is better.
Below 2 is considered healthy (always use industry average).
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to shareholders equity ratio in their analysis

It shows how much debt the company uses to finance their operations. Shareholders equity is whats left over when you subtract total liabilities from total assets. It's another way to meassure how much of Aurinia Pharmaceuticals Inc is financed with debt or own resources.

The three steps every investor should look at:

What is the current debt to equity ratio?
The current most recent quarter (MRQ) quickRatio of Aurinia Pharmaceuticals Inc is 0.45. This means that Aurinia Pharmaceuticals Inc can pay off $0.45 for each $1 in debt.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is 0.39.
What is the trend?
The trend is important because it shows you how Aurinia Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Aurinia Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Aurinia Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Not all debt is equally risky (for example, short term risk is less risky).

How to calculate debt to equity ratio

Debt to equity ratio = total debt \ shareholders equity.

Real life example Aurinia Pharmaceuticals Inc

You need the following data to determine equity ratio:

Balance sheet
Debt to equity ratio = total debt \ shareholders equity
170,108 \ 377,954 = 0.45 or 45.0%

Debt to equity measures the total debt versus the total shareholders equity. While the total debts to total assets ratio uses total assets, the debt to equity ratio looks at the total equity of shareholders. Where equity of shareholders are:

Common shares.
Preferred shares.
Retained earnings.

You can find the shareholders' equity in the balance sheet. A ratio between 0,5 and 1,5 is preferred. If the ratio is above 1.5, that would indicate creditors have significantly more stake (debt) in the company than the shareholders. In other words, the company is using a lot of debt to finance their operations.

Not all debt is equally risky. Meaning you can adjust the ratio by including or excluding certain amounts of debt. Short term debts are less risky because they have to be paid back within one year anyway. It’s much easier to plan one year ahead versus five or ten years.

2. Market Valuation of Aurinia Pharmaceuticals Inc

2.1. Earnings Per Share

2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Aurinia Pharmaceuticals Inc generates.

Above 15 is considered overpriced but always compare Aurinia Pharmaceuticals Inc to the Biotechnology industry mean.
A PE ratio of -12.09 means the investor is paying $-12.09 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Aurinia Pharmaceuticals Inc:

The EOD is -6.767. Based on the earnings, the company is expensive. -2
The MRQ is -12.094. Based on the earnings, the company is expensive. -2
The TTM is -19.640. Based on the earnings, the company is expensive. -2

Trends

Current period		Compared to		+/-
EOD	-6.767	MRQ	-12.094	+5.327
MRQ	-12.094	TTM	-19.640	+7.546
TTM	-19.640	YOY	-14.592	-5.048
TTM	-19.640	5Y	-18.659	-0.981
5Y	-18.659	10Y	-17.918	-0.742

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	-6.767	-2.264	-4.503
MRQ	-12.094	-2.629	-9.465
TTM	-19.640	-2.680	-16.960
YOY	-14.592	-4.145	-10.447
5Y	-18.659	-6.257	-12.402
10Y	-17.918	-6.254	-11.664

Measures how much money you pay for each share for every $1 in earnings Aurinia Pharmaceuticals Inc generates.

Indicates if the company’s shares are under or overvalued.

How to use PE ratio

Above 15 is considered overpriced but is hard to determine. Always compare Aurinia Pharmaceuticals Inc to the Biotechnology industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use PE ratio in their analysis

The PE ratio tells investors the current sentiment in the market for that company. As with every stock, the stock price never shows the real valuation of a company but rather how the market thinks how much the stock is worth.

In other words, the current stock price also incorporates any future earnings or business opportunities in the future. The best example is the stock market crash in 2000. The PE ratio for any internet based company was going through the roof. Only based on the general assumption the internet and all associated businesses would thrive in the future. But this was based on nothing. A business still needs a good product or service to be able to survive. Instead, every investor bought any stock which did something related to the internet. Result: huge market crash.

Many investors were willing to pay premium prices and that was causing the PE ratio to rise. A high PE ratio is a warning sign that investors might be overvaluing a stock based on future earnings.

The three steps every investor should look at:

What is the current PE Ratio?
The current most recent quarter (MRQ) PE Ratio of Aurinia Pharmaceuticals Inc is -12.09. This means the investor is paying $-12.09 for every $1 in earnings.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Biotechnology industry is -2.63.
What is the trend?
The trend is important because it shows you how Aurinia Pharmaceuticals Inc is performing over time. The most recent quarter might be important if Aurinia Pharmaceuticals Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Aurinia Pharmaceuticals Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Some industries might have very high or very low PE ratios in general.
PE ratios can be high for several years, it does not mean a sudden collapse is imminent.
Earnings growth is not included in the PE ratio.

How to calculate PE ratio

PE ratio = market value per share \ earnings per share

Real life example Aurinia Pharmaceuticals Inc

You need the following data to determine the PE ratio:

Balance sheet
Income statement

The PE ratio is a very commonly used ratio to determine the value of a company by comparing the current stock price relative to its earnings per share (EPS). Before we can calculate the PE ratio we need to know the EPS. EPS is calculated as follows:

EPS = (net profit - preferred dividends) \ end of period outstanding shares*
Net profit = revenue - expenses
0 \ 143,833 = EPS
PE ratio MRQ = -12.09

* The net profit minus preferred dividends can be found in the incomestatement as netIncomeApplicableToCommonShares.

The PE value helps investors to determine if the current stock price is under or overvalued. It also projects future growth.

In general, a higher PE ratio means that investors predict higher future growth. If the PE ratio is too high, then investors expect way too much future growth the company can never fulfil. This is most likely to happen in faster moving companies like tech companies or automobile companies like Tesla. These are hot and booming markets where investors expect much future growth driven by new technology (electric cars). When looking at the current MRQ (most recent quarter) PE ratio of Tesla ( jan. 2021) it's about 247 while the average in the industry is only 6. That might be a clue that Tesla is trading for way too high prices compared to their current assets and is more based on future growth.

2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Aurinia Pharmaceuticals Inc:

The EOD is 12.316. Based on how much money comes from the company's main activities, the company is cheap. +2
The MRQ is 22.012. Based on how much money comes from the company's main activities, the company is underpriced. +1
The TTM is -31.566. Based on how much money comes from the company's main activities, the company is expensive. -2

Trends

Current period		Compared to		+/-
EOD	12.316	MRQ	22.012	-9.696
MRQ	22.012	TTM	-31.566	+53.578
TTM	-31.566	YOY	-6.350	-25.216
TTM	-31.566	5Y	5.965	-37.531
5Y	5.965	10Y	-8.294	+14.259

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	12.316	-2.973	+15.289
MRQ	22.012	-3.333	+25.345
TTM	-31.566	-3.553	-28.013
YOY	-6.350	-5.605	-0.745
5Y	5.965	-8.376	+14.341
10Y	-8.294	-8.865	+0.571

2. Book Value per Share

2.3. Price to Book Ratio

Measures if the stock price of Aurinia Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

At or below 1 is considered healthy (always compare to Biotechnology industry mean).
A PB ratio of 3.44 means the investor is paying $3.44 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Aurinia Pharmaceuticals Inc:

The EOD is 1.925. Based on the equity, the company is underpriced. +1
The MRQ is 3.440. Based on the equity, the company is fair priced.
The TTM is 3.484. Based on the equity, the company is fair priced.

Trends

Current period		Compared to		+/-
EOD	1.925	MRQ	3.440	-1.515
MRQ	3.440	TTM	3.484	-0.044
TTM	3.484	YOY	2.884	+0.600
TTM	3.484	5Y	5.656	-2.172
5Y	5.656	10Y	8.616	-2.959

Compared to industry (Biotechnology)

Period	Company	Industry (mean)	+/-
EOD	1.925	1.896	+0.029
MRQ	3.440	2.115	+1.325
TTM	3.484	2.093	+1.391
YOY	2.884	2.884	0.000
5Y	5.656	3.542	+2.114
10Y	8.616	3.916	+4.700

2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Aurinia Pharmaceuticals Inc.

3.1. Institutions holding Aurinia Pharmaceuticals Inc

Institutions are holding 38.629% of the shares of Aurinia Pharmaceuticals Inc.

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2023-12-31	Armistice Capital, LLC	6.5939	1.1703	9536000	3488000	57.672
2023-12-31	BlackRock Inc	6.1687	0.002	8921049	508652	6.0465
2023-12-31	Goldman Sachs Group Inc	2.8329	0.0033	4096912	2624576	178.2593
2023-12-31	NEA Management Company, LLC	2.7451	2.3786	3969834	0	0
2023-12-31	State Street Corporation	1.87	0.0012	2704382	104847	4.0333
2023-12-31	Nuveen Asset Management, LLC	1.6264	0.0068	2352125	-338	-0.0144
2023-12-31	Geode Capital Management, LLC	1.085	0.0015	1569136	81342	5.4673
2023-12-31	Vanguard Group Inc	1.0436	0.0003	1509161	24893	1.6771
2023-12-31	Morgan Stanley - Brokerage Accounts	1.006	0.0012	1454826	31418	2.2072
2023-12-31	Citigroup Inc	0.9797	0.009	1416834	532884	60.2844
2023-12-31	Northern Trust Corp	0.7379	0.0017	1067175	21794	2.0848
2023-09-30	International Biotechnology Trust PLC	0.7195	2.7201	1040530	467000	81.4256
2023-12-31	Schroder Investment Management Group	0.7195	0.0121	1040530	1040530	0
2023-12-31	Susquehanna International Group, LLP	0.714	0.0018	1032604	424708	69.8652
2023-12-31	Balyasny Asset Management LLC	0.6134	0.015	887014	624186	237.4884
2023-09-30	TANG CAPITAL MANAGEMENT LLC	0.5186	0.8223	750000	600000	400
2023-12-31	Group One Trading, LP	0.4694	0.0161	678840	94458	16.1637
2023-12-31	Woodline Partners LP	0.4461	0.0631	645194	145194	29.0388
2023-09-30	Citadel Advisors Llc	0.4411	0.0011	637904	275906	76.2175
2023-12-31	Charles Schwab Investment Management Inc	0.303	0.001	438191	52891	13.7272
Total		31.6338	7.2285	45748241	+11142941	+24.4%

3.2. Funds holding Aurinia Pharmaceuticals Inc

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2024-03-28	iShares Russell 2000 ETF	2.3045	0.0254	3314592	1599	0.0483
2024-01-31	Fidelity Small Cap Index	0.9528	0.0417	1370434	21422	1.588
2024-03-28	iShares Russell 2000 Growth ETF	0.8143	0.0504	1171298	-1362	-0.1161
2024-01-31	CREF Stock R1	0.7275	0.0067	1046431	0	0
2024-01-31	International Biotechnology Ord	0.7234	2.3826	1040530	0	0
2024-03-28	iShares Biotechnology ETF	0.6569	0.062	944804	0	0
2024-01-31	TIAA-CREF Quant Small-Cap Equity Instl	0.57	0.2064	819850	63980	8.4644
2024-02-29	State St Russell Sm/Mid Cp® Indx NL Cl C	0.5565	0.011	800400	6600	0.8314
2024-02-29	GS Glb Sm Cp CORE Eq Base Inc USD Close	0.3697	0.3454	531726	0	0
2024-02-29	Vanguard Russell 2000 ETF	0.3422	0.0295	492154	38452	8.4752
2024-03-31	State St Russell Sm Cap® Indx SL Cl I	0.3391	0.0251	487752	0	0
2024-02-29	Vanguard Health Care ETF	0.3228	0.0127	464247	2368	0.5127
2023-12-31	NT R2000 Growth Index Fund - NL	0.2815	0.0984	404869	-3771	-0.9228
2024-01-31	AQA Selective Income C USD Acc	0.2781	1.9718	400000	0	0
2023-12-31	NT R2000 Index Fund - NL	0.27	0.0481	388313	-2945	-0.7527
2024-01-31	Goldman Sachs Small Cp Val Insghts Instl	0.2438	0.3044	350613	25148	7.7268
2024-02-29	Schwab Small Cap Index	0.2156	0.03	310097	-5002	-1.5874
2023-12-31	NT R2000 Index Fund - DC - NL - 2	0.2126	0.0482	305800	-3508	-1.1341
2023-12-31	NT R2000 Growth Index Fund - L	0.2115	0.0985	304252	17279	6.0211
2023-12-31	Northern Trust Russell 2000 Growth Index	0.2115	0.0989	304252	17279	6.0211
Total		10.6043	5.8972	15252414	+177539	+1.2%

3.3. Insider Transactions

Insiders are holding 7.446% of the shares of Aurinia Pharmaceuticals Inc.

Date	Owner	Type	Amount	Price	Post Transaction Amount	Link
2023-05-23	David R.w. Jayne	SELL	8733	11.26
2023-05-19	Joseph P Hagan	SELL	272	10.58

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Aurinia Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

	End of day	+/-	Most Recent Quarter	Trailing 12 Months	+/-	Year-Over-Year	+/-	5 Year	+/-	10 Year	+/-
Book Value Change Per Share	-	-	-0.096	-0.048	-51%	-0.127	+32%	0.092	-205%	0.063	-253%
Book Value Per Share	-	-	2.613	2.684	-3%	2.940	-11%	2.318	+13%	1.437	+82%
Current Ratio	-	-	5.503	7.024	-22%	11.952	-54%	13.742	-60%	14.748	-63%
Debt To Asset Ratio	-	-	0.310	0.256	+21%	0.127	+144%	0.168	+85%	0.210	+48%
Debt To Equity Ratio	-	-	0.450	0.356	+27%	0.146	+209%	0.208	+116%	0.291	+55%
Dividend Per Share	-	-	-	-	0%	-	0%	-	0%	-	0%
Eps	-	-	-0.186	-0.135	-27%	-0.187	+1%	-0.205	+10%	-0.143	-23%
Free Cash Flow Per Share	-	-	0.102	-0.058	+157%	-0.138	+235%	-0.143	+240%	-0.097	+195%
Free Cash Flow To Equity Per Share	-	-	0.064	-0.067	+205%	-0.133	+309%	0.084	-24%	0.064	-1%
Gross Profit Margin	-	-	1.000	1.000	0%	1.000	0%	1.000	0%	1.000	0%
Intrinsic Value_10Y_max	-	-	1.996	-	-	-	-	-	-	-	-
Intrinsic Value_10Y_min	-	-	-3.059	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_max	-	-	-0.302	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_min	-	-	-0.577	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_max	-	-	-0.526	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_min	-	-	-1.510	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_max	-	-	-0.287	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_min	-	-	-2.190	-	-	-	-	-	-	-	-
Market Cap	727428540.000	-79%	1300115820.000	1352178300.000	-4%	1239014715.000	+5%	1739863003.500	-25%	1170682710.000	+11%
Net Profit Margin	-	-	-0.596	-0.470	-21%	-1.019	+71%	-324.965	+54428%	-288.881	+48373%
Operating Margin	-	-	-0.457	-0.461	+1%	-1.049	+130%	-259.455	+56697%	-200.654	+43825%
Operating Ratio	-	-	1.457	1.501	-3%	2.047	-29%	364.647	-100%	325.936	-100%
Pb Ratio	1.925	-79%	3.440	3.484	-1%	2.884	+19%	5.656	-39%	8.616	-60%
Pe Ratio	-6.767	+44%	-12.094	-19.640	+62%	-14.592	+21%	-18.659	+54%	-17.918	+48%
Price Per Share	5.030	-79%	8.990	9.350	-4%	8.568	+5%	12.031	-25%	8.095	+11%
Price To Free Cash Flow Ratio	12.316	-79%	22.012	-31.566	+243%	-6.350	+129%	5.965	+269%	-8.294	+138%
Price To Total Gains Ratio	-52.247	+44%	-93.379	-540.869	+479%	-830.713	+790%	-305.325	+227%	-145.543	+56%
Quick Ratio	-	-	8.760	10.923	-20%	18.081	-52%	17.323	-49%	17.709	-51%
Return On Assets	-	-	-0.049	-0.038	-22%	-0.055	+13%	-0.080	+63%	-0.092	+88%
Return On Equity	-	-	-0.071	-0.050	-29%	-0.063	-11%	-0.096	+34%	-0.123	+74%
Total Gains Per Share	-	-	-0.096	-0.048	-51%	-0.127	+32%	0.092	-205%	0.063	-253%
Usd Book Value	-	-	377954000.000	388132750.000	-3%	425187750.000	-11%	335227000.000	+13%	207810050.000	+82%
Usd Book Value Change Per Share	-	-	-0.096	-0.048	-51%	-0.127	+32%	0.092	-205%	0.063	-253%
Usd Book Value Per Share	-	-	2.613	2.684	-3%	2.940	-11%	2.318	+13%	1.437	+82%
Usd Dividend Per Share	-	-	-	-	0%	-	0%	-	0%	-	0%
Usd Eps	-	-	-0.186	-0.135	-27%	-0.187	+1%	-0.205	+10%	-0.143	-23%
Usd Free Cash Flow	-	-	14765976.000	-8409506.000	+157%	-19901300.250	+235%	-20658211.250	+240%	-13989530.625	+195%
Usd Free Cash Flow Per Share	-	-	0.102	-0.058	+157%	-0.138	+235%	-0.143	+240%	-0.097	+195%
Usd Free Cash Flow To Equity Per Share	-	-	0.064	-0.067	+205%	-0.133	+309%	0.084	-24%	0.064	-1%
Usd Market Cap	727428540.000	-79%	1300115820.000	1352178300.000	-4%	1239014715.000	+5%	1739863003.500	-25%	1170682710.000	+11%
Usd Price Per Share	5.030	-79%	8.990	9.350	-4%	8.568	+5%	12.031	-25%	8.095	+11%
Usd Profit	-	-	-26875000.000	-19505000.000	-27%	-27045000.000	+1%	-28959950.000	+8%	-19311975.000	-28%
Usd Revenue	-	-	45095000.000	43878250.000	+3%	33507500.000	+35%	20279200.000	+122%	10178825.000	+343%
Usd Total Gains Per Share	-	-	-0.096	-0.048	-51%	-0.127	+32%	0.092	-205%	0.063	-253%
	EOD	+4 -4	MRQ	TTM	+11 -22	YOY	+21 -12	5Y	+18 -15	10Y	+17 -16

4.2. Fundamental Score

Let's check the fundamental score of Aurinia Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

Indicator	Condition		Value
Price to Earnings Ratio (EOD)	Between	0-15	-6.767
Price to Book Ratio (EOD)	Between	0-1	1.925
Net Profit Margin (MRQ)	Greater than	0	-0.596
Operating Margin (MRQ)	Greater than	0	-0.457
Quick Ratio (MRQ)	Greater than	1	8.760
Current Ratio (MRQ)	Greater than	1	5.503
Debt to Asset Ratio (MRQ)	Less than	1	0.310
Debt to Equity Ratio (MRQ)	Less than	1	0.450
Return on Equity (MRQ)	Greater than	0.15	-0.071
Return on Assets (MRQ)	Greater than	0.05	-0.049
Total			4/10 (40.0%)

Create your own Stock Scanner

Investing is personal. The best investors buy stocks based on their own analysis. Create your personal Stock Scanner with the key performance indicators that are important to you.
Create your own Stock Scanner

4.3. Technical Score

Let's check the technical score of Aurinia Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Rsi	Greater than	50	44.473
Ma 20	Greater than	Ma 50	5.050
Ma 50	Greater than	Ma 100	5.408
Ma 100	Greater than	Ma 200	6.940
Open	Greater than	Close	5.090
Total			1/5 (20.0%)

Create your own Symbol Scanner

Trading is personal. The best traders buy and sell based on their own technical analysis. Create your personal Symbol Scanner with the technical indicators that are important to you.
Create your own Symbol Scanner

Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

		2022-12-31		2023-03-31		2023-06-30		2023-09-30		2023-12-31
Total Other Income Expense Net		2,909	905	3,814	222	4,036	-922	3,114	-8,930	-5,816

Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary

Total Assets	548,062
Total Liabilities	170,108
Total Stockholder Equity	377,954

	As reported
Total Liabilities	170,108
Total Stockholder Equity	+ 377,954
Total Assets	= 548,062

Assets

Total Assets	548,062
Total Current Assets	424,800
Long-term Assets	123,262

Total Current Assets

Total Current Assets (as reported)	424,800
Cash And Cash Equivalents	48,875
Short-term Investments	301,614
Net Receivables	24,089
Inventory	39,705
Other Current Assets	10,517
Total Current Assets (calculated)	424,800
+/-	0

Long-term Assets

Long-term Assets (as reported)	123,262
Property Plant Equipment	116,567
Long Term Investments	201
Intangible Assets	4,977
Long-term Assets Other	1,517
Long-term Assets (calculated)	123,262
+/-	0

Liabilities & Shareholders' Equity

Total Current Liabilities	77,188
Long-term Liabilities	92,920
Total Stockholder Equity	377,954

Total Current Liabilities

Total Current Liabilities (as reported)	77,188
Short-term Debt	15,598
Accounts payable	4,327
Other Current Liabilities	52,450
Total Current Liabilities (calculated)	72,375
+/-	4,813

Long-term Liabilities

Long-term Liabilities (as reported)	92,920
Capital Lease Obligations Min Short Term Debt	82,009
Long-term Liabilities Other	10,911
Long-term Liabilities (calculated)	92,920
+/-	0

Total Stockholder Equity

Total Stockholder Equity (as reported)	377,954
Common Stock	1,200,218
Retained Earnings	-942,322
Accumulated Other Comprehensive Income	-730
Other Stockholders Equity	120,788
Total Stockholder Equity (calculated)	377,954
+/-	0

Other

Capital Stock	1,200,218
Cash and Short Term Investments	350,489
Common Stock Shares Outstanding	143,833
Current Deferred Revenue	4,813
Liabilities and Stockholders Equity	548,062
Net Debt	48,732
Net Invested Capital	377,954
Net Working Capital	347,612
Property Plant and Equipment Gross	118,477
Short Long Term Debt Total	97,607

Balance Sheet

Currency in USD. All numbers in thousands.

Trend

2023-12-31

2023-09-30

2023-06-30

2023-03-31

2022-12-31

2022-09-30

2022-06-30

2022-03-31

2021-12-31

2021-09-30

2021-06-30

2021-03-31

2020-12-31

2020-09-30

2020-06-30

2020-03-31

2019-12-31

2019-09-30

2019-06-30

2019-03-31

2018-12-31

2018-09-30

2018-06-30

2018-03-31

2017-12-31

2017-09-30

2017-06-30

2017-03-31

2016-12-31

2016-09-30

2016-06-30

2016-03-31

2015-12-31

2015-09-30

2015-06-30

2015-03-31

2014-12-31

2014-09-30

2014-06-30

2014-03-31

2013-12-31

2013-09-30

2013-06-30

2013-03-31

2012-12-31

2012-09-30

2012-06-30

2012-03-31

2011-12-31

2011-09-30

2011-06-30

2011-03-31

2010-12-31

2010-09-30

2010-06-30

2010-03-31

2009-12-31

2009-09-30

2009-06-30

2009-03-31

2008-12-31

2008-09-30

2008-06-30

2008-03-31

2007-12-31

2007-09-30

2007-06-30

2007-03-31

2006-12-31

2006-09-30

2006-06-30

2006-03-31

2005-12-31

2005-09-30

2005-06-30

2005-03-31

2004-12-31

2004-09-30

2004-06-30

2004-03-31

2003-12-31

2003-09-30

2003-06-30

2003-03-31

2002-12-31

2002-09-30

2002-06-30

2002-03-31

2001-12-31

2001-09-30

2001-06-30

2001-03-31

2000-12-31

2000-09-30

2000-06-30

2000-03-31

1999-12-31

1999-09-30

1999-06-30

1999-03-31

1998-12-31

> Total Assets

2,585
2,645
1,873
4,143
4,824
12,547
12,164
13,968
12,217
11,132
30,596
30,155
37,062
38,123
53,859
53,050
50,679
49,709
66,565
75,992
74,434
70,545
64,237
65,205
61,173
53,163
46,236
60,546
54,350
47,806
44,800
38,925
30,637
56,637
53,822
47,975
42,667
30,523
39,117
33,342
26,658
13,313
10,638
10,810
9,547
9,621
8,054
12,535
10,282
15,136
19,336
20,124
14,321
9,739
9,004
7,740
4,160
3,644
3,874
23,328
23,142
63,276
60,179
56,395
52,378
48,008
44,383
38,943
33,567
27,749
30,186
33,250
56,997
219,694
207,800
199,832
189,847
176,410
167,855
157,695
145,863
164,501
151,237
150,844
326,683
314,972
295,278
461,750
463,661
417,078
386,268
360,066
543,367
506,902
482,148
488,293
470,860
451,761
548,900
555,013
548,062

548,062

555,013

548,900

451,761

470,860

488,293

482,148

506,902

543,367

360,066

386,268

417,078

463,661

461,750

295,278

314,972

326,683

150,844

151,237

164,501

145,863

157,695

167,855

176,410

189,847

199,832

207,800

219,694

56,997

33,250

30,186

27,749

33,567

38,943

44,383

48,008

52,378

56,395

60,179

63,276

23,142

23,328

3,874

3,644

4,160

7,740

9,004

9,739

14,321

20,124

19,336

15,136

10,282

12,535

8,054

9,621

9,547

10,810

10,638

13,313

26,658

33,342

39,117

30,523

42,667

47,975

53,822

56,637

30,637

38,925

44,800

47,806

54,350

60,546

46,236

53,163

61,173

65,205

64,237

70,545

74,434

75,992

66,565

49,709

50,679

53,050

53,859

38,123

37,062

30,155

30,596

11,132

12,217

13,968

12,164

12,547

4,824

4,143

1,873

2,645

2,585

> Total Current Assets

1,657
1,696
803
3,056
3,653
11,212
10,987
12,593
10,758
9,485
28,526
0
0
34,467
49,796
47,659
43,829
41,784
57,435
66,566
64,112
60,596
55,467
55,682
52,286
44,628
38,100
52,846
46,854
40,481
37,272
31,600
23,632
49,740
46,613
40,383
35,323
23,723
32,482
27,206
21,747
8,885
6,506
6,536
5,404
5,597
4,546
9,153
6,579
10,559
11,737
11,755
8,317
5,371
4,910
3,537
444
261
680
4,756
2,094
43,527
40,613
37,181
33,551
29,569
26,285
21,406
16,534
11,102
13,901
17,323
41,418
204,475
192,491
184,885
175,252
161,982
153,799
144,047
132,848
151,424
138,523
138,638
315,137
297,897
278,019
411,640
419,427
372,246
349,689
329,219
513,324
477,618
453,193
459,702
442,539
423,648
415,907
426,469
424,800

424,800

426,469

415,907

423,648

442,539

459,702

453,193

477,618

513,324

329,219

349,689

372,246

419,427

411,640

278,019

297,897

315,137

138,638

138,523

151,424

132,848

144,047

153,799

161,982

175,252

184,885

192,491

204,475

41,418

17,323

13,901

11,102

16,534

21,406

26,285

29,569

33,551

37,181

40,613

43,527

2,094

4,756

680

261

444

3,537

4,910

5,371

8,317

11,755

11,737

10,559

6,579

9,153

4,546

5,597

5,404

6,536

6,506

8,885

21,747

27,206

32,482

23,723

35,323

40,383

46,613

49,740

23,632

31,600

37,272

40,481

46,854

52,846

38,100

44,628

52,286

55,682

55,467

60,596

64,112

66,566

57,435

41,784

43,829

47,659

49,796

34,467

28,526

9,485

10,758

12,593

10,987

11,212

3,653

3,056

803

1,696

1,657

Cash And Cash Equivalents

1,193
0
134
2,581
2,894
10,545
10,336
5,321
9,511
1,912
16,789
0
30,802
30,379
41,565
39,452
19,851
17,340
33,210
42,291
27,624
21,251
25,107
21,453
14,881
12,277
9,229
19,332
16,706
14,685
15,074
15,673
13,361
41,518
40,374
35,849
32,339
20,808
29,787
26,491
21,118
4,619
6,314
5,848
4,583
5,069
3,981
7,002
6,348
10,173
8,643
7,333
5,924
3,346
1,350
289
185
33
454
4,502
1,819
43,289
39,093
25,533
22,706
19,042
15,728
10,594
5,756
3,492
9,125
12,333
39,649
199,066
179,717
87,546
165,629
131,227
132,302
114,898
117,967
140,359
131,493
134,539
306,019
274,207
264,350
248,758
272,350
156,591
121,561
57,587
231,900
132,542
151,632
86,052
94,172
89,001
81,707
46,397
48,875

48,875

46,397

81,707

89,001

94,172

86,052

151,632

132,542

231,900

57,587

121,561

156,591

272,350

248,758

264,350

274,207

306,019

134,539

131,493

140,359

117,967

114,898

132,302

131,227

165,629

87,546

179,717

199,066

39,649

12,333

9,125

3,492

5,756

10,594

15,728

19,042

22,706

25,533

39,093

43,289

1,819

4,502

454

185

289

1,350

3,346

5,924

7,333

8,643

10,173

6,348

7,002

3,981

5,069

4,583

5,848

6,314

4,619

21,118

26,491

29,787

20,808

32,339

35,849

40,374

41,518

13,361

15,673

15,074

14,685

16,706

19,332

9,229

12,277

14,881

21,453

25,107

21,251

27,624

42,291

33,210

17,340

19,851

39,452

41,565

30,379

30,802

16,789

1,912

9,511

5,321

10,336

10,545

2,894

2,581

134

1,193

Short-term Investments

0
1,085
0
0
0
0
0
6,471
6,659
6,461
10,223
0
2,663
2,658
2,795
5,396
20,931
21,971
22,595
22,931
35,226
37,923
28,588
32,764
35,206
30,726
27,334
31,881
28,780
23,839
19,908
13,898
8,729
6,614
4,786
3,338
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
857
0
0
0
0
0
0
0
0
0
9,994
9,998
9,999
10,008
9,989
9,997
7,040
2,999
3,047
0
3,050
10,071
94,860
7,833
27,905
17,899
23,985
7,889
3,975
0
0
0
11,913
31,936
143,284
125,979
191,668
197,176
228,813
234,178
286,210
240,104
290,592
295,218
272,533
269,006
291,503
301,614

301,614

291,503

269,006

272,533

295,218

290,592

240,104

286,210

234,178

228,813

197,176

191,668

125,979

143,284

31,936

11,913

3,975

7,889

23,985

17,899

27,905

7,833

94,860

10,071

3,050

3,047

2,999

7,040

9,997

9,989

10,008

9,999

9,998

9,994

857

3,338

4,786

6,614

8,729

13,898

19,908

23,839

28,780

31,881

27,334

30,726

35,206

32,764

28,588

37,923

35,226

22,931

22,595

21,971

20,931

5,396

2,795

2,658

2,663

10,223

6,461

6,659

6,471

1,085

Net Receivables

265
203
335
136
276
200
141
154
492
363
278
0
0
401
4,434
1,881
2,231
1,438
370
237
288
275
211
384
347
339
302
394
385
362
342
331
397
492
357
297
489
467
398
272
407
250
104
511
735
264
449
1,935
114
228
223
220
279
973
564
212
184
184
179
79
106
100
114
50
92
114
85
55
47
47
49
98
86
123
285
415
109
225
307
759
217
376
248
470
368
3,511
508
1,127
1,018
1,187
4,418
9,814
15,414
20,401
18,173
41,771
13,483
19,046
19,499
37,946
24,089

24,089

37,946

19,499

19,046

13,483

41,771

18,173

20,401

15,414

9,814

4,418

1,187

1,018

1,127

508

3,511

368

470

248

376

217

759

307

225

109

415

285

123

114

100

106

179

184

212

564

973

279

220

223

228

114

1,935

449

264

735

511

104

250

407

272

398

467

489

297

357

492

397

331

342

362

385

394

302

339

347

384

211

275

288

237

370

1,438

2,231

1,881

4,434

401

278

363

492

154

141

200

276

136

335

203

265

Inventory

199
339
335
340
413
467
479
559
581
557
721
710
546
509
568
522
516
590
605
561
561
530
590
613
603
614
643
554
269
277
297
326
257
179
304
442
2,007
1,897
1,906
210
120
181
0
0
0
97
0
0
0
0
133
196
195
0
2,672
2,785
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-109
0
0
0
0
0
0
0
0
0
0
6,757
13,927
15,936
17,376
19,293
19,326
26,266
25,863
25,320
24,752
31,745
33,155
32,820
39,705

39,705

32,820

33,155

31,745

24,752

25,320

25,863

26,266

19,326

19,293

17,376

15,936

13,927

6,757

-109

2,785

2,672

195

196

133

181

120

210

1,906

1,897

2,007

442

304

179

257

326

297

277

269

554

643

614

603

613

590

530

561

605

590

516

522

568

509

546

710

721

557

581

559

479

467

413

340

335

339

199

> Long-term Assets

928
949
1,071
1,087
1,172
1,335
1,177
1,375
1,460
1,646
2,069
0
0
3,655
4,063
5,391
6,850
7,925
9,130
9,426
10,322
9,949
8,769
9,524
8,887
8,535
8,136
7,701
7,496
7,325
7,528
7,325
7,005
6,897
7,209
7,593
7,344
6,800
6,635
6,136
4,911
4,428
4,132
4,274
4,143
4,024
3,508
3,382
3,703
4,578
7,598
8,369
6,004
4,368
4,094
4,203
3,715
3,383
3,194
18,572
21,048
19,749
19,566
19,214
18,827
18,439
18,098
17,537
17,033
16,647
16,285
15,927
15,579
15,219
15,309
14,947
14,595
14,428
14,056
13,648
13,015
13,077
12,714
12,206
11,546
17,075
17,259
50,110
44,234
44,832
36,579
30,847
30,043
29,284
28,955
28,591
28,321
28,113
132,993
128,544
123,262

123,262

128,544

132,993

28,113

28,321

28,591

28,955

29,284

30,043

30,847

36,579

44,832

44,234

50,110

17,259

17,075

11,546

12,206

12,714

13,077

13,015

13,648

14,056

14,428

14,595

14,947

15,309

15,219

15,579

15,927

16,285

16,647

17,033

17,537

18,098

18,439

18,827

19,214

19,566

19,749

21,048

18,572

3,194

3,383

3,715

4,203

4,094

4,368

6,004

8,369

7,598

4,578

3,703

3,382

3,508

4,024

4,143

4,274

4,132

4,428

4,911

6,136

6,635

6,800

7,344

7,593

7,209

6,897

7,005

7,325

7,528

7,325

7,496

7,701

8,136

8,535

8,887

9,524

8,769

9,949

10,322

9,426

9,130

7,925

6,850

5,391

4,063

3,655

2,069

1,646

1,460

1,375

1,177

1,335

1,172

1,087

1,071

949

928

Property Plant Equipment

530
475
535
475
482
667
616
827
858
928
1,247
1,229
1,215
2,779
2,974
4,127
5,712
6,594
7,627
7,826
8,603
8,197
7,152
7,682
7,099
6,731
6,322
6,000
5,602
5,266
5,312
5,091
4,771
4,548
4,602
4,633
4,350
3,890
3,677
3,276
2,634
2,342
2,159
2,146
1,982
1,822
1,580
1,418
1,264
1,116
934
703
649
516
362
227
88
73
58
47
37
25
59
52
52
51
47
42
36
32
27
26
29
26
32
27
31
50
44
39
41
441
425
406
93
5,922
6,423
9,663
10,275
10,519
10,428
10,083
9,801
9,564
9,262
8,703
8,557
8,655
125,792
121,174
116,567

116,567

121,174

125,792

8,655

8,557

8,703

9,262

9,564

9,801

10,083

10,428

10,519

10,275

9,663

6,423

5,922

406

425

441

227

362

516

649

703

934

1,116

1,264

1,418

1,580

1,822

1,982

2,146

2,159

2,342

2,634

3,276

3,677

3,890

4,350

4,633

4,602

4,548

4,771

5,091

5,312

5,266

5,602

6,000

6,322

6,731

7,099

7,682

7,152

8,197

8,603

7,826

7,627

6,594

5,712

4,127

2,974

2,779

1,215

1,229

1,247

928

858

827

616

667

482

475

535

475

530

Long Term Investments

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
28,797
24,380
12,603
5,004
0
0
0
0
0
0
0
0
591
201

201

591

5,004

12,603

24,380

28,797

Intangible Assets

398
475
535
543
620
667
561
548
601
0
823
0
859
877
1,089
1,264
1,138
1,331
1,503
1,600
1,719
1,752
1,617
1,842
1,788
1,804
1,814
1,700
1,894
2,059
2,216
2,234
2,234
2,349
2,607
2,959
2,994
2,910
2,958
2,860
2,277
2,086
1,973
2,128
2,161
2,202
1,929
1,965
2,011
3,461
3,433
3,164
3,182
3,200
3,083
3,133
3,032
2,902
2,787
18,525
20,859
19,579
19,223
18,878
18,489
18,102
17,765
17,354
16,997
16,615
16,258
15,901
15,550
15,193
14,829
14,472
14,116
13,720
13,354
12,951
12,616
12,278
11,931
11,591
11,244
10,944
10,627
11,441
9,332
9,854
9,291
8,926
8,404
7,882
7,338
6,839
6,425
6,101
5,683
5,261
4,977

4,977

5,261

5,683

6,101

6,425

6,839

7,338

7,882

8,404

8,926

9,291

9,854

9,332

11,441

10,627

10,944

11,244

11,591

11,931

12,278

12,616

12,951

13,354

13,720

14,116

14,472

14,829

15,193

15,550

15,901

16,258

16,615

16,997

17,354

17,765

18,102

18,489

18,878

19,223

19,579

20,859

18,525

2,787

2,902

3,032

3,133

3,083

3,200

3,182

3,164

3,433

3,461

2,011

1,965

1,929

2,202

2,161

2,128

1,973

2,086

2,277

2,860

2,958

2,910

2,994

2,959

2,607

2,349

2,234

2,216

2,059

1,894

1,700

1,814

1,804

1,788

1,842

1,617

1,752

1,719

1,600

1,503

1,331

1,138

1,264

1,089

877

859

823

601

548

561

667

620

543

535

475

398

Other Assets

0
0
0
0
644
662
0
0
0
584
729
811
859
875
0
1,264
1,139
1,331
1,503
1,599
1,719
1,754
1,617
0
1,786
0
1,813
1,699
1,887
0
2,210
2,235
2,233
2,343
2,627
0
2,975
2,919
2,949
0
2,277
2,089
1,970
2,128
2,151
2,211
1,910
0
2,447
0
6,699
0
0
3,879
3,733
3,985
0
0
3,144
0
0
19,724
19,507
19,162
18,775
18,388
18,051
17,495
16,997
16,615
16,258
15,901
15,550
15,193
15,277
14,920
14,564
658
658
658
358
358
358
209
209
209
209
209
5,736
11,856
386,268
11,838
11,838
11,838
12,355
13,049
13,339
0
1,518
0
0

1,518

13,339

13,049

12,355

11,838

386,268

11,856

5,736

209

358

658

14,564

14,920

15,277

15,193

15,550

15,901

16,258

16,615

16,997

17,495

18,051

18,388

18,775

19,162

19,507

19,724

3,144

3,985

3,733

3,879

6,699

2,447

1,910

2,211

2,151

2,128

1,970

2,089

2,277

2,949

2,919

2,975

2,627

2,343

2,233

2,235

2,210

1,887

1,699

1,813

1,786

1,617

1,754

1,719

1,599

1,503

1,331

1,139

1,264

875

859

811

729

584

662

644

> Total Liabilities

1,724
1,831
1,004
951
758
1,001
818
1,210
884
1,124
4,039
3,981
1,780
1,954
4,228
3,135
3,120
3,049
3,804
4,034
5,891
5,583
3,203
7,877
8,973
7,234
7,045
8,882
11,992
9,937
10,731
11,132
10,470
10,213
12,674
11,202
14,252
7,936
21,391
19,766
18,788
8,991
3,529
4,734
4,739
3,850
2,824
4,447
3,934
9,228
8,518
7,655
7,910
3,582
5,232
5,532
6,278
6,565
6,768
11,098
9,842
8,655
9,106
7,079
7,272
20,449
16,370
15,405
13,604
11,724
10,647
13,147
21,047
47,031
29,335
32,188
24,104
23,956
25,685
32,353
33,288
25,156
25,369
27,103
53,167
51,564
56,239
62,907
55,911
46,850
54,011
61,894
64,276
58,779
58,380
64,868
65,425
61,353
156,608
163,136
170,108

170,108

163,136

156,608

61,353

65,425

64,868

58,380

58,779

64,276

61,894

54,011

46,850

55,911

62,907

56,239

51,564

53,167

27,103

25,369

25,156

33,288

32,353

25,685

23,956

24,104

32,188

29,335

47,031

21,047

13,147

10,647

11,724

13,604

15,405

16,370

20,449

7,272

7,079

9,106

8,655

9,842

11,098

6,768

6,565

6,278

5,532

5,232

3,582

7,910

7,655

8,518

9,228

3,934

4,447

2,824

3,850

4,739

4,734

3,529

8,991

18,788

19,766

21,391

7,936

14,252

11,202

12,674

10,213

10,470

11,132

10,731

9,937

11,992

8,882

7,045

7,234

8,973

7,877

3,203

5,583

5,891

4,034

3,804

3,049

3,120

3,135

4,228

1,954

1,780

3,981

4,039

1,124

884

1,210

818

1,001

758

951

1,004

1,831

1,724

> Total Current Liabilities

1,657
1,763
803
883
620
868
744
1,152
834
1,083
4,008
3,950
1,722
1,730
4,027
2,977
2,991
2,936
3,493
3,794
5,361
5,126
2,798
4,403
5,266
3,816
4,115
6,340
9,545
7,934
6,652
7,055
6,930
6,980
9,317
7,655
10,741
4,600
7,570
9,343
9,130
5,455
2,551
3,273
3,245
2,380
1,534
2,960
1,344
2,775
2,136
1,568
2,126
1,224
3,008
3,323
3,672
4,103
4,471
6,948
6,042
4,487
4,734
2,655
2,836
2,397
3,723
3,965
3,617
3,642
3,921
4,766
7,930
8,316
3,627
6,855
8,150
5,311
5,076
6,884
7,261
6,496
7,300
13,515
11,295
14,178
17,143
23,889
31,997
21,151
29,315
37,537
40,646
33,838
34,626
41,765
46,107
42,046
61,661
73,890
77,188

77,188

73,890

61,661

42,046

46,107

41,765

34,626

33,838

40,646

37,537

29,315

21,151

31,997

23,889

17,143

14,178

11,295

13,515

7,300

6,496

7,261

6,884

5,076

5,311

8,150

6,855

3,627

8,316

7,930

4,766

3,921

3,642

3,617

3,965

3,723

2,397

2,836

2,655

4,734

4,487

6,042

6,948

4,471

4,103

3,672

3,323

3,008

1,224

2,126

1,568

2,136

2,775

1,344

2,960

1,534

2,380

3,245

3,273

2,551

5,455

9,130

9,343

7,570

4,600

10,741

7,655

9,317

6,980

6,930

7,055

6,652

7,934

9,545

6,340

4,115

3,816

5,266

4,403

2,798

5,126

5,361

3,794

3,493

2,936

2,991

2,977

4,027

1,730

1,722

3,950

4,008

1,083

834

1,152

744

868

620

883

803

1,763

1,657

Short-term Debt

464
949
67
68
69
133
105
48
44
40
35
0
0
136
136
132
131
187
245
240
187
188
168
959
1,403
1,326
1,441
1,477
1,625
1,672
1,407
1,715
1,722
1,625
1,313
928
532
237
2,478
3,532
4,750
1,680
14
0
0
0
0
128
0
0
0
0
44
46
46
49
36
28
23
8
1,317
0
0
0
0
0
0
0
0
0
0
0
2,928
0
0
0
4,068
0
0
0
-118
106
122
125
6,906
0
0
0
788
1,075
1,112
1,111
1,059
1,009
953
918
936
945
14,970
14,308
15,598

15,598

14,308

14,970

945

936

918

953

1,009

1,059

1,111

1,112

1,075

788

6,906

125

122

106

-118

4,068

2,928

1,317

128

1,680

4,750

3,532

2,478

237

532

928

1,313

1,625

1,722

1,715

1,407

1,672

1,625

1,477

1,441

1,326

1,403

959

168

188

187

240

245

187

131

132

136

105

133

949

464

Short Long Term Debt

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,241
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
106
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

106

1,241

Accounts payable

994
814
736
747
551
734
640
1,103
791
1,043
3,972
3,915
1,651
1,594
3,891
2,845
2,221
2,750
3,248
3,554
4,540
4,869
2,562
3,372
3,787
2,415
2,600
3,285
4,864
4,298
3,063
4,170
3,273
4,932
7,572
6,292
9,798
3,968
4,692
3,586
3,274
3,086
733
1,690
2,034
1,441
950
1,015
856
652
953
479
768
843
978
2,955
1,165
2,070
2,511
1,072
1,104
1,436
2,643
2,283
1,392
2,025
3,351
3,617
2,079
2,149
2,462
2,932
2,863
6,132
3,439
6,665
3,773
5,121
4,886
6,694
7,071
6,200
6,749
13,272
4,153
11,177
13,641
2,212
2,635
2,182
2,535
3,263
3,879
3,267
32,380
40,123
3,087
3,680
4,808
8,854
4,327

4,327

8,854

4,808

3,680

3,087

40,123

32,380

3,267

3,879

3,263

2,535

2,182

2,635

2,212

13,641

11,177

4,153

13,272

6,749

6,200

7,071

6,694

4,886

5,121

3,773

6,665

3,439

6,132

2,863

2,932

2,462

2,149

2,079

3,617

3,351

2,025

1,392

2,283

2,643

1,436

1,104

1,072

2,511

2,070

1,165

2,955

978

843

768

479

953

652

856

1,015

950

1,441

2,034

1,690

733

3,086

3,274

3,586

4,692

3,968

9,798

6,292

7,572

4,932

3,273

4,170

3,063

4,298

4,864

3,285

2,600

2,415

3,787

3,372

2,562

4,869

4,540

3,554

3,248

2,750

2,221

2,845

3,891

1,594

1,651

3,915

3,972

1,043

791

1,103

640

734

551

747

736

814

994

Other Current Liabilities

199
0
0
68
0
0
0
0
0
0
0
0
0
0
0
0
640
0
0
0
70
69
68
72
76
75
74
78
53
52
55
14
1,292
14
15
16
16
16
16
15
3,287
3,082
734
1,705
2,059
1,459
974
1,028
869
1,564
964
702
94
31
2,663
12
2,131
1,673
1,614
5,574
3,393
4,270
4,516
2,438
1,227
2,180
3,506
3,772
1,370
3,499
3,803
4,648
2,021
8,198
3,509
6,737
191
5,193
4,958
6,766
190
72
311
13,272
118
14,060
17,025
23,771
7,200
2,382
2,372
6,456
4,640
29,562
33,673
40,847
38,936
34,264
38,655
46,066
52,450

52,450

46,066

38,655

34,264

38,936

40,847

33,673

29,562

4,640

6,456

2,372

2,382

7,200

23,771

17,025

14,060

118

13,272

311

190

6,766

4,958

5,193

191

6,737

3,509

8,198

2,021

4,648

3,803

3,499

1,370

3,772

3,506

2,180

1,227

2,438

4,516

4,270

3,393

5,574

1,614

1,673

2,131

2,663

702

964

1,564

869

1,028

974

1,459

2,059

1,705

734

3,082

3,287

1,292

640

199

> Long-term Liabilities

66
68
201
68
138
133
74
58
50
41
31
0
0
224
201
159
129
112
311
240
530
458
405
3,474
3,707
3,418
2,930
2,542
2,447
2,002
4,079
4,077
3,540
3,233
3,357
3,547
3,511
3,336
13,821
10,422
9,658
3,536
978
1,461
1,494
1,470
1,290
1,487
2,591
6,453
6,382
6,088
5,784
2,358
2,224
2,209
2,606
2,462
2,297
4,150
3,800
4,168
4,372
4,424
4,436
18,052
12,647
11,440
9,987
8,082
6,726
8,381
13,117
38,715
25,708
25,333
15,954
18,645
20,609
25,469
26,027
18,660
18,069
13,588
41,872
37,386
39,096
39,018
23,914
25,699
24,696
24,357
23,630
24,941
23,754
23,103
19,318
19,307
94,947
89,246
92,920

92,920

89,246

94,947

19,307

19,318

23,103

23,754

24,941

23,630

24,357

24,696

25,699

23,914

39,018

39,096

37,386

41,872

13,588

18,069

18,660

26,027

25,469

20,609

18,645

15,954

25,333

25,708

38,715

13,117

8,381

6,726

8,082

9,987

11,440

12,647

18,052

4,436

4,424

4,372

4,168

3,800

4,150

2,297

2,462

2,606

2,209

2,224

2,358

5,784

6,088

6,382

6,453

2,591

1,487

1,290

1,470

1,494

1,461

978

3,536

9,658

10,422

13,821

3,336

3,511

3,547

3,357

3,233

3,540

4,077

4,079

2,002

2,447

2,542

2,930

3,418

3,707

3,474

405

458

530

240

311

112

129

159

201

224

133

138

201

Long term Debt Total

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
315
290
253
0
5,851
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

5,851

253

290

315

Other Liabilities

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
291
271
249
246
239
218
197
188
107
93
2,301
3,030
2,926
2,946
3,222
3,429
3,407
3,306
3,318
1,093
1,528
1,690
976
1,461
1,487
1,476
1,277
1,177
2,599
6,465
6,416
6,016
5,756
2,351
2,213
2,213
2,613
2,464
2,303
4,152
3,809
4,168
4,372
4,424
4,436
18,052
12,647
11,440
9,987
8,082
6,726
8,381
13,117
38,715
25,708
25,333
15,954
18,645
20,609
25,469
26,027
18,345
17,779
13,335
41,872
31,535
32,894
11,018
16,295
17,893
16,872
16,562
15,950
17,379
16,323
15,833
12,166
0
8,711
0
0

8,711

12,166

15,833

16,323

17,379

15,950

16,562

16,872

17,893

16,295

11,018

32,894

31,535

41,872

13,335

17,779

18,345

26,027

25,469

20,609

18,645

15,954

25,333

25,708

38,715

13,117

8,381

6,726

8,082

9,987

11,440

12,647

18,052

4,436

4,424

4,372

4,168

3,809

4,152

2,303

2,464

2,613

2,213

2,351

5,756

6,016

6,416

6,465

2,599

1,177

1,277

1,476

1,487

1,461

976

1,690

1,528

1,093

3,318

3,306

3,407

3,429

3,222

2,946

2,926

3,030

2,301

107

188

197

218

239

246

249

271

291

Deferred Long Term Liability

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
847
0
0
0
678
0
0
0
560
0
0
0
442
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

442

560

678

847

> Total Stockholder Equity

862
814
870
3,192
4,066
11,546
11,346
12,759
11,333
10,008
26,557
26,174
35,283
36,168
49,631
49,915
47,559
46,660
62,761
71,958
68,543
64,962
61,034
57,328
52,199
45,929
39,191
51,664
42,357
37,869
34,068
27,793
20,166
46,423
41,148
36,774
28,415
22,586
17,725
13,576
7,870
4,322
7,109
6,076
4,809
5,771
5,230
8,089
6,348
5,908
10,818
12,469
6,411
6,157
3,772
2,208
-2,119
-2,921
-2,894
12,231
13,301
54,621
51,073
49,316
45,106
27,559
28,013
23,538
19,963
16,025
19,539
20,103
35,950
172,663
178,465
167,644
165,743
152,454
142,170
125,342
112,575
139,345
125,868
123,741
273,516
263,408
239,039
398,843
407,750
370,228
332,257
298,172
479,091
448,123
423,768
423,425
405,435
390,408
392,292
391,877
377,954

377,954

391,877

392,292

390,408

405,435

423,425

423,768

448,123

479,091

298,172

332,257

370,228

407,750

398,843

239,039

263,408

273,516

123,741

125,868

139,345

112,575

125,342

142,170

152,454

165,743

167,644

178,465

172,663

35,950

20,103

19,539

16,025

19,963

23,538

28,013

27,559

45,106

49,316

51,073

54,621

13,301

12,231

-2,894

-2,921

-2,119

2,208

3,772

6,157

6,411

12,469

10,818

5,908

6,348

8,089

5,230

5,771

4,809

6,076

7,109

4,322

7,870

13,576

17,725

22,586

28,415

36,774

41,148

46,423

20,166

27,793

34,068

37,869

42,357

51,664

39,191

45,929

52,199

57,328

61,034

64,962

68,543

71,958

62,761

46,660

47,559

49,915

49,631

36,168

35,283

26,174

26,557

10,008

11,333

12,759

11,346

11,546

4,066

3,192

870

814

862

Common Stock

0
0
0
0
11,850
20,727
22,093
0
26,403
25,600
28,552
45,991
55,126
57,933
70,560
67,416
67,181
71,817
89,745
102,609
107,816
105,980
104,133
110,003
115,474
114,872
113,710
135,645
135,345
135,402
141,652
141,843
135,754
166,530
182,418
194,358
193,344
187,804
188,724
181,030
158,371
152,820
168,766
183,317
186,262
192,976
184,084
192,392
201,530
209,370
210,848
193,440
199,207
205,017
199,755
206,791
204,703
200,152
194,392
213,724
207,068
257,084
257,131
257,790
258,494
260,926
261,546
261,645
261,645
261,645
267,516
275,805
299,815
487,965
496,726
498,698
499,200
499,200
503,688
503,699
504,650
543,063
543,824
559,073
790,472
794,932
796,350
986,468
944,328
952,673
954,572
967,159
1,177,051
1,178,807
1,180,884
1,184,020
1,185,309
1,193,019
1,196,480
1,198,560
1,200,218

1,200,218

1,198,560

1,196,480

1,193,019

1,185,309

1,184,020

1,180,884

1,178,807

1,177,051

967,159

954,572

952,673

944,328

986,468

796,350

794,932

790,472

559,073

543,824

543,063

504,650

503,699

503,688

499,200

498,698

496,726

487,965

299,815

275,805

267,516

261,645

261,546

260,926

258,494

257,790

257,131

257,084

207,068

213,724

194,392

200,152

204,703

206,791

199,755

205,017

199,207

193,440

210,848

209,370

201,530

192,392

184,084

192,976

186,262

183,317

168,766

152,820

158,371

181,030

188,724

187,804

193,344

194,358

182,418

166,530

135,754

141,843

141,652

135,402

135,345

135,645

113,710

114,872

115,474

110,003

104,133

105,980

107,816

102,609

89,745

71,817

67,181

67,416

70,560

57,933

55,126

45,991

28,552

25,600

26,403

22,093

20,727

11,850

Retained Earnings

-942,322

-915,447

-902,000

-890,508

-864,302

-838,256

-829,267

-793,752

-756,122

-722,800

-672,545

-625,535

-575,156

-619,930

-585,866

-556,340

-539,806

-463,326

-444,289

-428,388

-415,960

-401,367

-383,025

-367,318

-351,840

-348,508

-335,388

-332,989

-281,048

-272,715

-265,296

-262,020

-257,753

-253,690

-248,480

-247,747

-236,372

-231,453

-228,933

-224,916

-205,371

-213,451

-206,953

-213,037

-217,084

-214,147

-205,557

-207,203

-202,032

-192,488

-208,552

-212,684

-203,821

-195,009

-189,413

-195,384

-190,975

-185,626

-169,357

-155,336

-157,776

-176,810

-180,246

-172,955

-174,377

-165,421

-147,365

-127,380

-119,417

-117,835

-111,814

-101,147

-96,913

-87,424

-77,714

-72,096

-65,539

-54,816

-45,018

-42,303

-39,843

-32,006

-27,450

-26,214

-20,525

-17,495

-20,915

-21,881

-20,106

-18,108

-15,013

-12,899

-10,737

-9,143

-7,718

-6,927

-5,888

-6,036

-5,502

Accumulated Other Comprehensive Income

-398
-407
-401
-543
-551
-534
-543
-713
0
0
-707
0
0
-941
-990
-946
-1,026
-1,101
472
499
551
574
1,111
1,195
1,272
2,287
2,260
2,426
942
938
982
-5,187
-5,944
2,706
2,933
4,947
3,153
3,033
3,235
5,237
-7,404
0
0
0
-8,713
0
0
0
-9,765
0
0
0
-10,189
0
0
0
-10,869
-174
-213
0
-4,762
-805
-805
-805
-805
-805
-805
-805
-805
-805
-805
-805
-805
-805
-805
-894
-883
-805
-805
-805
-805
-805
-805
-805
-805
-805
-805
-805
-805
-799
-792
-794
-852
-1,618
-1,853
-1,527
-1,061
-988
-1,020
-947
-730

-730

-947

-1,020

-988

-1,061

-1,527

-1,853

-1,618

-852

-794

-792

-799

-805

-883

-894

-805

-4,762

-213

-174

-10,869

-10,189

-9,765

-8,713

-7,404

5,237

3,235

3,033

3,153

4,947

2,933

2,706

-5,944

-5,187

982

938

942

2,426

2,260

2,287

1,272

1,195

1,111

574

551

499

472

-1,101

-1,026

-946

-990

-941

-707

-713

-543

-534

-551

-543

-401

-407

-398

Capital Surplus

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
24,690
25,475
27,138
28,799
23,655
25,621
0
0
39,383
43,889
51,022
54,607
59,014
64,686
74,004
79,188
0
88,885
98,832
0
0

98,832

88,885

79,188

74,004

64,686

59,014

54,607

51,022

43,889

39,383

25,621

23,655

28,799

27,138

25,475

24,690

Treasury Stock

Other Stockholders Equity

6,762
7,257
7,159
10,662
12,336
21,223
22,626
26,371
26,346
28,115
47,369
0
0
58,991
71,536
68,356
69,110
73,976
89,739
103,466
107,836
106,691
104,941
110,950
116,466
115,739
114,645
136,662
138,329
138,078
144,900
150,816
145,527
171,097
185,580
197,248
199,640
192,509
194,736
185,149
173,051
159,658
7,700
8,385
204,496
201,155
194,643
203,097
219,935
218,592
219,370
204,957
218,633
213,361
209,329
216,355
21,131
10,138
9,881
11,958
16,365
23,258
23,680
23,784
23,789
15,185
15,752
16,388
16,876
17,205
18,124
17,818
17,988
18,492
17,932
18,348
19,266
21,377
22,312
23,815
24,690
25,475
27,138
28,799
23,655
25,621
240,039
33,110
39,383
43,889
51,022
54,607
59,014
64,686
74,004
79,188
85,489
88,885
98,832
109,711
120,788

120,788

109,711

98,832

88,885

85,489

79,188

74,004

64,686

59,014

54,607

51,022

43,889

39,383

33,110

240,039

25,621

23,655

28,799

27,138

25,475

24,690

23,815

22,312

21,377

19,266

18,348

17,932

18,492

17,988

17,818

18,124

17,205

16,876

16,388

15,752

15,185

23,789

23,784

23,680

23,258

16,365

11,958

9,881

10,138

21,131

216,355

209,329

213,361

218,633

204,957

219,370

218,592

219,935

203,097

194,643

201,155

204,496

8,385

7,700

159,658

173,051

185,149

194,736

192,509

199,640

197,248

185,580

171,097

145,527

150,816

144,900

138,078

138,329

136,662

114,645

115,739

116,466

110,950

104,941

106,691

107,836

103,466

89,739

73,976

69,110

68,356

71,536

58,991

47,369

28,115

26,346

26,371

22,626

21,223

12,336

10,662

7,159

7,257

6,762

Balance Sheet

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31	2001-12-31	2000-12-31	1999-12-31	1998-12-31
Accounts Payable	4,327	3,087	3,879	2,635	4,153	7,071	3,773	2,863	2,079	1,392	1,104	1,165	768	856	2,034	3,274	9,798	3,273	4,864	3,787	4,540	2,221	1,651	1,103	747	1,172
Accumulated Amortization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Accumulated Depreciation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Accumulated Other Comprehensive Income	-730	-1,061	-852	-805	-805	-805	-883	-805	-805	-805	-4,762	-10,869	-10,189	-9,765	-8,713	-7,404	3,153	-5,944	942	1,272	551	-1,026	-943	-713	-543	-391
Additional Paid In Capital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	97,607	8,088	8,739	8,407	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Stock	1,200,218	1,185,309	1,177,051	944,328	790,472	504,650	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Surpluse	0	0	59,014	39,383	23,655	24,690	18,360	17,017	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash	48,875	94,172	231,900	272,350	306,019	117,967	165,629	39,649	5,756	22,706	1,819	185	5,924	6,348	4,583	21,118	32,339	13,361	16,706	14,881	27,624	19,851	30,803	5,321	2,581	0
Cash And Equivalents	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash And Short Term Investments	350,489	389,390	466,078	398,329	306,019	125,856	173,462	39,649	15,753	32,704	1,819	185	5,924	6,348	4,583	21,118	32,339	22,090	45,486	50,087	62,850	40,782	33,465	11,791	2,581	0
Common Stock	1,200,218	1,185,309	1,177,051	944,328	790,472	504,650	499,200	299,815	261,645	258,494	207,068	204,703	199,207	201,530	186,262	158,371	193,344	135,754	135,345	115,474	107,816	67,181	55,126	26,403	0	0
Common Stock Shares Outstanding	143,236	141,915	129,369	118,473	93,024	84,782	76,948	35,285	32,154	29,158	6,344	3,552	3,459	2,549	2,394	2,125	2,070	1,685	1,581	1,508	1,407	1,289	1,025	749	543	486
Common Stock Total Equity	0	0	1,177,051	944,328	790,472	504,650	499,200	299,815	261,645	258,494	207,068	204,703	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Current Deferred Revenue	4,813	3,148	31,068	21,374	118	118	118	118	168	217	227	340	1,220	475	1,186	1,093	395	643	3,004	0	564	0	0	0	0	0
Deferred Long Term Asset Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Deferred Long Term Liab	0	0	0	0	0	0	442	560	678	847	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Earning Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Good Will	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Intangible Assets	4,977	6,425	8,404	9,332	11,244	12,616	14,116	15,550	16,997	18,489	20,859	3,032	3,182	2,011	2,161	2,277	2,994	2,234	1,894	1,788	1,719	1,138	859	548	543	391
Inventory	39,705	24,752	19,326	13,927	0	0	-109	0	0	0	0	0	195	0	0	120	2,007	257	269	603	561	516	546	559	340	130
Liabilities And Stockholders Equity	548,062	470,860	543,367	463,661	326,683	145,863	189,847	56,997	33,567	52,378	23,142	4,160	14,321	10,282	9,547	26,658	42,667	30,637	54,350	61,173	74,434	50,679	37,063	13,968	4,143	1,563
Long Term Debt	0	0	0	0	0	0	11,793	9,138	5,499	11,235	0	0	35	0	0	8,132	81	612	2,330	3,466	238	129	57	60	0	0
Long Term Debt Total	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Long Term Investments	201	0	0	24,380	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Negative Goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Debt	48,732	-86,084	-223,161	-263,943	-306,019	-117,967	-165,629	-39,649	-5,756	-22,706	-1,819	-149	-5,844	-6,348	-4,583	-8,190	-31,725	-11,027	-12,742	-10,010	-27,199	-19,591	-30,674	-5,215	-2,445	260
Net Invested Capital	377,954	405,435	479,091	407,750	273,516	112,575	165,743	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Receivables	24,089	13,483	15,414	1,018	368	217	109	86	47	92	106	184	279	114	735	407	489	397	385	347	288	2,231	387	154	136	195
Net Tangible Assets	0	399,010	470,687	398,418	289,738	99,959	151,627	20,400	2,966	15,382	-7,125	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Working Capital	347,612	396,432	472,678	387,430	303,842	125,587	167,102	33,488	12,917	30,715	-3,947	-3,228	6,191	5,235	2,159	12,617	24,581	16,701	37,308	47,019	58,751	40,838	33,265	11,442	2,173	-1,758
Non Current Assets Total	123,262	28,321	30,043	44,234	11,546	13,015	14,595	15,579	17,033	18,827	21,048	3,715	6,004	3,703	4,143	4,911	7,344	7,005	7,496	8,887	10,322	6,850	2,075	1,375	1,087	977
Non Current Liabilities Other	10,911	12,166	15,950	1,589	12,313	3,956	3,719	3,419	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Current Liabilities Total	92,920	19,318	23,630	23,914	41,872	26,027	15,954	13,117	9,987	4,436	3,800	2,606	5,784	2,591	1,494	9,658	3,511	3,540	2,447	3,707	530	129	57	58	68	65
Non Currrent Assets Other	1,517	13,339	11,838	247	209	358	448	15,579	0	286	152	0	2,172	429	0	0	0	0	0	0	0	0	0	0	68	0
Noncontrolling Interest In Consolidated Entity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Assets	0	13,339	11,838	5,736	209	358	448	0	0	286	0	0	0	430	0	0	0	0	0	0	0	0	0	0	0	0
Other Current Assets	10,517	1,334	796	6,153	8,750	6,775	1,790	1,683	734	755	169	75	1,920	117	86	102	488	888	715	404	413	299	589	89	0	260
Other Current Liab	52,450	38,936	4,640	7,200	118	190	191	2,021	1,370	1,227	1,598	2,131	94	869	2,059	3,287	16	1,292	53	76	70	640	0	0	68	977
Other Liab	0	12,166	15,950	16,295	14,406	26,027	15,954	13,117	9,987	4,436	3,809	2,613	5,756	2,599	1,487	1,528	3,407	2,926	107	239	291	0	0	0	0	0
Other Stockholder Equity	120,788	85,489	59,014	39,383	23,655	24,690	19,266	17,988	16,876	23,789	16,365	21,131	218,633	219,935	204,496	173,051	199,640	145,527	138,329	116,466	107,836	69,110	56,070	26,371	10,662	5,013
Preferred Stock Redeemable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Total Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Property Plant And Equipment Gross	118,477	8,557	9,801	10,275	93	41	31	29	36	52	37	88	649	1,264	1,982	2,634	4,350	4,771	5,602	7,099	8,603	5,712	1,215	827	475	586
Property Plant And Equipment Net	116,567	8,557	9,801	10,275	93	41	31	29	36	52	37	88	649	1,264	1,982	2,634	4,350	4,771	5,602	7,099	8,603	5,712	1,215	827	475	586
Property Plant Equipment	0	8,557	9,801	4,786	93	41	31	29	36	52	37	89	650	1,268	1,972	2,635	4,322	4,770	5,580	7,094	8,601	5,718	1,215	851	0	0
Retained Earnings	-942,322	-864,302	-756,122	-575,156	-539,806	-415,960	-351,840	-281,048	-257,753	-236,372	-205,371	-217,084	-202,032	-203,821	-190,975	-157,776	-174,377	-119,417	-96,913	-65,539	-39,843	-20,525	-19,844	-12,899	-6,927	-5,469
Retained Earnings Total Equity	0	0	-756,122	-575,156	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Short Long Term Debt	0	0	0	0	0	0	0	0	0	0	1,241	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Short Long Term Debt Total	97,607	8,088	8,739	8,407	0	0	0	0	0	0	0	36	79	0	0	12,929	614	2,334	3,964	4,871	425	260	128	106	136	260
Short Term Debt	15,598	936	1,059	788	6,906	-118	4,068	2,928	0	0	3,111	36	44	0	0	4,750	532	1,722	1,625	1,403	187	131	71	48	68	195
Short Term Investments	301,614	295,218	234,178	125,979	0	7,889	7,833	0	9,997	9,998	0	0	0	0	0	0	0	8,729	28,780	35,206	35,226	20,931	2,663	6,471	0	0
Temporary Equity Redeemable Noncontrolling Interests	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Assets	548,062	470,860	543,367	463,661	326,683	145,863	189,847	56,997	33,567	52,378	23,142	4,160	14,321	10,282	9,547	26,658	42,667	30,637	54,350	61,173	74,434	50,679	37,063	13,968	4,143	1,563
Total Current Assets	424,800	442,539	513,324	419,427	315,137	132,848	175,252	41,418	16,534	33,551	2,094	444	8,317	6,579	5,404	21,747	35,323	23,632	46,854	52,286	64,112	43,829	34,988	12,593	3,056	586
Total Current Liabilities	77,188	46,107	40,646	31,997	11,295	7,261	8,150	7,930	3,617	2,836	6,042	3,672	2,126	1,344	3,245	9,130	10,741	6,930	9,545	5,266	5,361	2,991	1,722	1,152	883	2,344
Total Liab	170,108	65,425	64,276	55,911	53,167	33,288	24,104	21,047	13,604	7,272	9,842	6,278	7,910	3,934	4,739	18,788	14,252	10,470	11,992	8,973	5,891	3,120	1,780	1,210	951	2,409
Total Permanent Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Stockholder Equity	377,954	405,435	479,091	407,750	273,516	112,575	165,743	35,950	19,963	45,106	13,301	-2,119	6,411	6,348	4,809	7,870	28,415	20,166	42,357	52,199	68,543	47,559	35,283	12,759	3,192	-846
Treasury Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Warrants	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31	2002-09-30	2002-06-30	2002-03-31	2001-12-31	2001-09-30	2001-06-30	2001-03-31	2000-12-31	2000-09-30	2000-06-30	2000-03-31	1999-12-31	1999-09-30	1999-06-30	1999-03-31	1998-12-31
Accounts Payable	4,327	8,854	4,808	3,680	3,087	40,123	32,380	3,267	3,879	3,263	2,535	2,182	2,635	2,212	13,641	11,177	4,153	13,272	6,749	6,200	7,071	6,694	4,886	5,121	3,773	6,665	3,439	6,132	2,863	2,932	2,462	2,149	2,079	3,617	3,351	2,025	1,392	2,283	2,643	1,436	1,104	1,072	2,511	2,070	1,165	2,955	978	843	768	479	953	652	856	1,015	950	1,441	2,034	1,690	733	3,086	3,274	3,586	4,692	3,968	9,798	6,292	7,572	4,932	3,273	4,170	3,063	4,298	4,864	3,285	2,600	2,415	3,787	3,372	2,562	4,869	4,540	3,554	3,248	2,750	2,221	2,845	3,891	1,594	1,651	3,915	3,972	1,043	791	1,103	640	734	551	747	736	814	994
Accumulated Amortization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Accumulated Depreciation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Accumulated Other Comprehensive Income	-730	-947	-1,020	-988	-1,061	-1,527	-1,853	-1,618	-852	-794	-792	-799	-805	-805	-805	-805	-805	-805	-805	-805	-805	-805	-805	-805	-883	-894	-805	-805	-805	-805	-805	-805	-805	-805	-805	-805	-805	-805	-805	-805	-4,762	0	-213	-174	-10,869	0	0	0	-10,189	0	0	0	-9,765	0	0	0	-8,713	0	0	0	-7,404	5,237	3,235	3,033	3,153	4,947	2,933	2,706	-5,944	-5,187	982	938	942	2,426	2,260	2,287	1,272	1,195	1,111	574	551	499	472	-1,101	-1,026	-946	-990	-941	0	0	-707	0	0	-713	-543	-534	-551	-543	-401	-407	-398
Additional Paid In Capital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	97,607	93,214	101,206	7,931	8,088	8,188	8,384	8,571	8,739	8,906	8,936	8,881	8,407	8,298	0	5,851	0	378	412	421	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Stock	1,200,218	1,198,560	1,196,480	1,193,019	1,185,309	1,184,020	1,180,884	1,178,807	1,177,051	967,159	954,572	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Surpluse	0	0	98,832	88,885	0	79,188	74,004	64,686	59,014	54,607	51,022	43,889	39,383	0	0	25,621	23,655	28,799	27,138	25,475	24,690	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash	48,875	46,397	81,707	89,001	94,172	86,052	151,632	132,542	231,900	57,587	121,561	156,591	272,350	248,758	264,350	274,207	306,019	134,539	131,493	140,359	117,967	114,898	132,302	131,227	165,629	87,546	179,717	199,066	39,649	12,333	9,125	3,492	5,756	10,594	15,728	19,042	22,706	25,533	39,093	43,289	1,819	4,502	454	33	185	289	1,350	3,346	5,924	7,333	8,643	10,173	6,348	7,002	3,981	5,069	4,583	5,848	6,314	4,619	21,118	26,491	29,787	20,808	32,339	35,849	40,374	41,518	13,361	15,673	15,074	14,685	16,706	19,332	9,229	12,277	14,881	21,453	25,107	21,251	27,624	42,291	33,210	17,340	19,851	39,452	41,565	30,379	30,802	0	16,789	1,912	9,511	5,321	10,336	10,545	2,894	2,581	134	0	1,193
Cash And Equivalents	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash And Short Term Investments	350,489	337,900	350,713	361,534	389,390	376,644	391,736	418,752	466,078	286,400	318,737	348,259	398,329	392,042	264,350	286,120	306,019	134,539	131,493	144,334	125,856	138,883	150,201	159,132	173,462	182,406	189,788	202,116	39,649	15,380	12,124	10,532	15,753	20,583	25,736	29,041	32,704	35,527	39,093	43,289	1,819	4,502	454	33	185	289	1,350	3,346	5,924	7,333	8,643	10,173	6,348	7,002	3,981	5,069	4,583	5,848	6,314	4,619	21,118	26,491	29,787	20,808	32,339	39,187	45,160	48,132	22,090	29,570	34,982	38,524	45,486	51,212	36,563	43,002	50,087	54,217	53,695	59,174	62,850	65,223	55,805	39,311	40,782	44,848	44,360	33,037	0	0	27,012	8,373	9,511	11,791	10,336	10,545	2,894	2,581	134	1,085	1,193
Common Stock	1,200,218	1,198,560	1,196,480	1,193,019	1,185,309	1,184,020	1,180,884	1,178,807	1,177,051	967,159	954,572	952,673	944,328	986,468	796,350	794,932	790,472	559,073	543,824	543,063	504,650	503,699	503,688	499,200	499,200	498,698	496,726	487,965	299,815	275,805	267,516	261,645	261,645	261,645	261,546	260,926	258,494	257,790	257,131	257,084	207,068	213,724	194,392	200,152	204,703	206,791	199,755	205,017	199,207	193,440	210,848	209,370	201,530	192,392	184,084	192,976	186,262	183,317	168,766	152,820	158,371	181,030	188,724	187,804	193,344	194,358	182,418	166,530	135,754	141,843	141,652	135,402	135,345	135,645	113,710	114,872	115,474	110,003	104,133	105,980	107,816	102,609	89,745	71,817	67,181	67,416	70,560	57,933	55,126	45,991	28,552	25,600	26,403	0	22,093	20,727	11,850	0	0	0	0
Common Stock Shares Outstanding	143,833	142,847	142,777	142,641	142,268	141,856	141,726	141,675	132,054	128,443	128,222	127,401	126,618	122,357	112,576	112,209	97,936	92,169	91,768	90,146	85,384	85,321	84,350	84,052	83,300	83,608	82,973	56,680	56,680	36,079	32,551	32,287	32,287	32,278	32,237	31,859	31,859	33,249	31,359	21,848	21,848	5,197	3,877	3,857	3,857	3,478	3,478	3,478	3,478	3,523	3,523	3,284	3,284	2,736	2,628	2,639	2,639	2,628	2,191	2,125	2,125	2,125	2,125	2,125	2,125	2,125	2,125	1,905	1,905	1,686	1,686	1,684	1,684	1,655	1,503	1,498	1,498	1,497	1,497	1,496	1,496	1,490	1,325	1,305	1,305	1,321	1,320	1,232	0	0	990	954	925	925	699	714	550	550	600	700	2,628
Common Stock Total Equity	0	0	1,196,480	1,193,019	0	1,184,020	1,180,884	1,178,807	1,177,051	967,159	954,572	952,673	944,328	986,468	796,350	794,932	790,472	559,073	543,824	543,063	504,650	503,699	503,688	499,200	499,200	498,698	496,726	487,965	299,815	275,805	267,516	261,645	261,645	261,645	261,546	260,926	258,494	257,790	257,131	257,084	207,068	213,724	194,392	200,152	204,703	0	0	0	0	0	0	0	0	0	0	0	0	183,317	168,766	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Current Deferred Revenue	4,813	4,662	3,228	3,157	3,148	0	0	0	31,068	26,707	23,296	15,512	21,374	118	118	118	118	118	118	118	118	118	118	118	118	118	118	118	118	118	118	143	168	193	217	217	217	217	218	217	227	294	323	333	340	308	298	304	1,220	866	1,172	1,211	475	1,804	560	921	1,186	1,567	1,804	693	1,093	2,210	384	380	395	419	417	408	643	1,156	2,127	1,912	3,004	1,500	0	0	0	0	0	0	564	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Deferred Long Term Asset Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Deferred Long Term Liab	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	442	0	0	0	560	0	0	0	678	0	0	0	847	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Earning Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Good Will	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Intangible Assets	4,977	5,261	5,683	6,101	6,425	6,839	7,338	7,882	8,404	8,926	9,291	9,854	9,332	11,441	10,627	10,944	11,244	11,591	11,931	12,278	12,616	12,951	13,354	13,720	14,116	14,472	14,829	15,193	15,550	15,901	16,258	16,615	16,997	17,354	17,765	18,102	18,489	18,878	19,223	19,579	20,859	18,525	2,787	2,902	3,032	3,133	3,083	3,200	3,182	3,164	3,433	3,461	2,011	1,965	1,929	2,202	2,161	2,128	1,973	2,086	2,277	2,860	2,958	2,910	2,994	2,959	2,607	2,349	2,234	2,234	2,216	2,059	1,894	1,700	1,814	1,804	1,788	1,842	1,617	1,752	1,719	1,600	1,503	1,331	1,138	1,264	1,089	877	859	0	823	0	601	548	561	667	620	543	535	475	398
Inventory	39,705	32,820	33,155	31,745	24,752	25,320	25,863	26,266	19,326	19,293	17,376	15,936	13,927	6,757	0	0	0	0	0	0	0	0	0	0	-109	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,785	2,672	0	195	196	133	0	0	0	0	97	0	0	0	181	120	210	1,906	1,897	2,007	442	304	179	257	326	297	277	269	554	643	614	603	613	590	530	561	561	605	590	516	522	568	509	546	710	721	557	581	559	479	467	413	340	335	339	199
Liabilities And Stockholders Equity	548,062	555,013	548,900	451,761	470,860	488,293	482,148	506,902	543,367	360,066	386,268	417,078	463,661	461,750	295,278	314,972	326,683	150,844	151,237	164,501	145,863	157,695	167,855	176,410	189,847	199,832	207,800	219,694	56,997	33,250	30,186	27,749	33,567	38,943	44,383	48,008	52,378	56,395	60,179	63,276	23,142	23,328	3,874	3,644	4,160	7,740	9,004	9,739	14,321	20,124	19,336	15,136	10,282	12,535	8,054	9,621	9,547	10,810	10,638	13,313	26,658	33,342	39,117	30,523	42,667	47,975	53,822	56,637	30,637	38,925	44,800	47,806	54,350	60,546	46,236	53,163	61,173	65,205	64,237	70,545	74,434	75,992	66,565	49,709	50,679	53,050	53,859	38,123	0	0	30,596	11,132	12,217	13,968	12,164	12,547	4,824	4,143	1,873	2,645	2,585
Long Term Debt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	315	0	0	0	0	11,793	0	0	0	9,138	0	0	0	5,499	0	0	0	11,235	0	0	0	0	0	0	0	0	0	12	24	35	0	0	0	0	314	0	0	0	0	0	1,851	8,132	9,272	10,458	41	81	122	161	278	612	1,050	1,767	1,904	2,330	2,353	2,731	3,201	3,466	3,226	156	187	238	240	311	112	129	159	201	224	57	31	42	49	60	0	74	87	86	0	0	0	0
Long Term Debt Total	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5,851	0	253	290	315	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Long Term Investments	201	591	0	0	0	0	0	0	0	0	5,004	12,603	24,380	28,797	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Negative Goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Debt	48,732	46,817	19,499	-81,070	-86,084	-77,864	-143,248	-123,971	-223,161	-48,681	-112,625	-147,710	-263,943	-240,460	-258,148	-268,356	-306,019	-134,161	-131,081	-139,938	-117,967	-114,898	-132,302	-131,227	-165,629	-87,546	-179,717	-199,066	-39,649	-12,333	-9,125	-3,492	-5,756	-10,594	-15,728	-19,042	-22,706	-25,533	-39,093	-43,289	-1,819	-4,494	-431	-6	-149	-240	-1,292	-3,276	-5,844	-7,333	-8,643	-10,173	-6,348	-6,561	-3,981	-5,069	-4,583	-5,848	-6,257	-1,048	-8,190	-13,635	-16,817	-20,530	-31,725	-34,800	-38,901	-39,613	-11,027	-12,909	-11,895	-11,105	-12,742	-15,501	-5,056	-7,751	-10,010	-17,266	-24,783	-20,877	-27,199	-41,812	-32,654	-17,041	-19,591	-39,162	-41,227	-30,018	0	0	-16,722	-1,831	-9,417	-5,215	-10,157	-10,345	-2,757	-2,445	67	1,017	-663
Net Invested Capital	377,954	391,877	392,292	390,408	405,435	423,425	423,768	448,123	479,091	298,172	332,257	370,228	407,750	398,843	0	263,408	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Receivables	24,089	37,946	19,499	19,046	13,483	41,771	18,173	20,401	15,414	9,814	4,418	1,187	1,018	1,127	508	3,511	368	470	248	376	217	759	307	225	109	415	285	123	86	98	49	47	47	55	85	114	92	50	114	100	106	79	179	184	184	212	564	973	279	220	223	228	114	1,935	449	264	735	511	104	250	407	272	398	467	489	297	357	492	397	331	342	362	385	394	302	339	347	384	211	275	288	237	370	1,438	2,231	1,881	4,434	401	0	0	278	363	492	154	141	200	276	136	335	203	265
Net Tangible Assets	0	0	392,292	390,408	399,010	423,425	416,430	448,123	470,687	289,246	322,966	360,374	398,418	400,410	228,412	252,464	262,272	112,150	113,937	127,067	99,959	112,391	128,816	138,734	151,627	153,172	163,636	157,470	20,400	0	0	0	2,966	0	0	0	15,382	0	0	0	-7,125	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Working Capital	347,612	352,579	354,246	381,602	396,432	417,937	418,567	443,780	472,678	291,682	320,374	351,095	387,430	387,751	260,876	283,719	303,842	125,123	131,223	144,928	125,587	137,163	148,723	156,671	167,102	178,030	188,864	196,159	33,488	12,557	9,980	7,460	12,917	17,441	22,562	27,172	30,715	34,526	35,879	39,040	-3,947	-2,192	-3,791	-3,842	-3,228	213	1,902	4,147	6,191	10,187	9,601	7,784	5,235	6,193	3,012	3,218	2,159	3,263	3,955	3,430	12,617	17,862	24,912	19,123	24,581	32,728	37,296	42,760	16,701	24,545	30,619	32,547	37,308	46,506	33,985	40,812	47,019	51,279	52,670	55,470	58,751	62,772	53,942	38,848	40,838	44,683	45,769	32,737	0	0	24,518	8,402	9,923	11,442	10,243	10,345	3,032	2,173	0	-68	0
Non Current Assets Total	123,262	128,544	132,993	28,113	28,321	28,591	28,955	29,284	30,043	30,847	36,579	44,832	44,234	50,110	17,259	17,075	11,546	12,206	12,714	13,077	13,015	13,648	14,056	14,428	14,595	14,947	15,309	15,219	15,579	15,927	16,285	16,647	17,033	17,537	18,098	18,439	18,827	19,214	19,566	19,749	21,048	18,572	3,194	3,383	3,715	4,203	4,094	4,368	6,004	8,369	7,598	4,578	3,703	3,382	3,508	4,024	4,143	4,274	4,132	4,428	4,911	6,136	6,635	6,800	7,344	7,593	7,209	6,897	7,005	7,325	7,528	7,325	7,496	7,701	8,136	8,535	8,887	9,524	8,769	9,949	10,322	9,426	9,130	7,925	6,850	5,391	4,063	3,655	0	0	2,069	1,646	1,460	1,375	1,177	1,335	1,172	1,087	1,071	949	928
Non Current Liabilities Other	10,911	10,340	88,133	12,321	12,166	15,833	16,323	17,379	15,950	16,562	16,872	17,893	1,589	10,750	16,645	11,860	12,313	4,135	4,037	3,949	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Current Liabilities Total	92,920	89,246	94,947	19,307	19,318	23,103	23,754	24,941	23,630	24,357	24,696	25,699	23,914	39,018	39,096	37,386	41,872	13,588	18,069	18,660	26,027	25,469	20,609	18,645	15,954	25,333	25,708	38,715	13,117	8,381	6,726	8,082	9,987	11,440	12,647	18,052	4,436	4,424	4,372	4,168	3,800	4,150	2,297	2,462	2,606	2,209	2,224	2,358	5,784	6,088	6,382	6,453	2,591	1,487	1,290	1,470	1,494	1,461	978	3,536	9,658	10,422	13,821	3,336	3,511	3,547	3,357	3,233	3,540	4,077	4,079	2,002	2,447	2,542	2,930	3,418	3,707	3,474	405	458	530	240	311	112	129	159	201	224	0	0	31	41	50	58	74	133	138	68	201	68	66
Non Currrent Assets Other	1,517	1,518	1,518	13,357	13,339	13,049	12,355	11,838	11,838	11,838	11,856	11,856	247	209	209	209	209	209	358	358	358	658	658	658	448	448	448	0	0	0	0	0	0	141	286	286	286	284	284	145	152	0	0	0	0	849	650	651	2,172	4,503	3,231	0	429	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	718	0	0	0	0	69	68	0	0	0
Noncontrolling Interest In Consolidated Entity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Assets	0	0	1,518	0	13,339	13,049	12,355	11,838	11,838	11,838	386,268	11,856	5,736	209	209	209	209	209	358	358	358	658	658	658	14,564	14,920	15,277	15,193	15,550	15,901	16,258	16,615	16,997	17,495	18,051	18,388	18,775	19,162	19,507	19,724	0	0	3,144	0	0	3,985	3,733	3,879	0	0	6,699	0	2,447	0	1,910	2,211	2,151	2,128	1,970	2,089	2,277	0	2,949	2,919	2,975	0	2,627	2,343	2,233	2,235	2,210	0	1,887	1,699	1,813	0	1,786	0	1,617	1,754	1,719	1,599	1,503	1,331	1,139	1,264	0	875	859	811	729	584	0	0	0	662	644	0	0	0	0
Other Current Assets	10,517	1,645	1,208	1,227	1,334	3,808	1,088	3,966	796	728	886	1,180	6,153	11,714	13,161	8,266	8,750	3,629	6,782	6,714	6,775	4,405	3,291	2,625	1,790	2,064	2,418	2,236	1,683	1,845	1,728	523	734	768	464	414	755	1,604	1,406	138	169	175	47	44	75	251	323	1,052	1,920	4,007	2,738	157	117	215	117	168	86	177	88	3,549	102	233	391	550	488	456	792	938	888	1,373	1,651	1,318	715	686	592	672	404	468	404	617	413	546	655	445	299	408	434	521	589	508	515	193	174	89	31	0	69	0	0	68	0
Other Current Liab	52,450	46,066	38,655	34,264	38,936	40,847	33,673	29,562	4,640	6,456	2,372	2,382	7,200	23,771	17,025	14,060	118	13,272	311	72	190	6,766	4,958	5,193	191	6,737	3,509	8,198	2,021	4,648	3,803	3,499	1,370	3,772	3,506	2,180	1,227	2,438	4,516	4,270	3,393	5,574	1,614	1,673	2,131	12	2,663	31	94	702	964	1,564	869	1,028	974	1,459	2,059	1,705	734	3,082	3,287	15	16	16	16	16	15	14	1,292	14	55	52	53	78	74	75	76	72	68	69	70	0	0	0	640	0	0	0	0	0	0	0	0	0	0	0	0	68	0	0	199
Other Liab	0	0	8,711	0	12,166	15,833	16,323	17,379	15,950	16,562	16,872	17,893	16,295	11,018	32,894	31,535	41,872	13,335	17,779	18,345	26,027	25,469	20,609	18,645	15,954	25,333	25,708	38,715	13,117	8,381	6,726	8,082	9,987	11,440	12,647	18,052	4,436	4,424	4,372	4,168	3,809	4,152	2,303	2,464	2,613	2,213	2,213	2,351	5,756	6,016	6,416	6,465	2,599	1,177	1,277	1,476	1,487	1,461	976	1,690	1,528	1,093	3,318	3,306	3,407	3,429	3,222	2,946	2,926	3,030	2,301	93	107	188	197	218	239	246	249	271	291	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Stockholder Equity	120,788	109,711	98,832	88,885	85,489	79,188	74,004	64,686	59,014	54,607	51,022	43,889	39,383	33,110	240,039	25,621	23,655	28,799	27,138	25,475	24,690	23,815	22,312	21,377	19,266	18,348	17,932	18,492	17,988	17,818	18,124	17,205	16,876	16,388	15,752	15,185	23,789	23,784	23,680	23,258	16,365	11,958	9,881	10,138	21,131	216,355	209,329	213,361	218,633	204,957	219,370	218,592	219,935	203,097	194,643	201,155	204,496	8,385	7,700	159,658	173,051	185,149	194,736	192,509	199,640	197,248	185,580	171,097	145,527	150,816	144,900	138,078	138,329	136,662	114,645	115,739	116,466	110,950	104,941	106,691	107,836	103,466	89,739	73,976	69,110	68,356	71,536	58,991	0	0	47,369	28,115	26,346	26,371	22,626	21,223	12,336	10,662	7,159	7,257	6,762
Preferred Stock Redeemable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Total Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Property Plant And Equipment Gross	118,477	122,928	127,392	8,655	8,557	10,012	0	0	0	0	0	10,519	10,275	9,663	6,423	5,922	93	406	425	441	41	39	44	50	31	27	32	26	29	26	27	32	36	42	47	51	52	52	59	25	37	47	58	73	88	227	362	516	649	703	934	1,116	1,264	1,418	1,580	1,822	1,982	2,146	2,159	2,342	2,634	3,276	3,677	3,890	4,350	4,633	4,602	4,548	4,771	5,091	5,312	5,266	5,602	6,000	6,322	6,731	7,099	7,682	7,152	8,197	8,603	7,826	7,627	6,594	5,712	4,127	2,974	2,779	0	0	1,247	928	858	827	616	667	482	475	535	475	530
Property Plant And Equipment Net	116,567	121,174	125,792	8,655	8,557	8,703	9,262	9,564	9,801	10,083	10,428	10,519	10,275	9,663	6,423	5,922	93	406	425	441	41	39	44	50	31	27	32	26	29	26	27	32	36	42	47	51	52	52	59	25	37	47	58	73	88	227	362	516	649	703	934	1,116	1,264	1,418	1,580	1,822	1,982	2,146	2,159	2,342	2,634	3,276	3,677	3,890	4,350	4,633	4,602	4,548	4,771	5,091	5,312	5,266	5,602	6,000	6,322	6,731	7,099	7,682	7,152	8,197	8,603	7,826	7,627	6,594	5,712	4,127	2,974	2,779	0	0	1,247	928	858	827	616	667	482	475	535	475	530
Property Plant Equipment	0	0	3,650	3,842	8,557	3,758	9,262	4,332	9,801	4,551	10,428	4,758	4,786	9,704	6,423	5,922	93	406	425	441	41	39	44	50	31	27	32	26	29	26	27	32	36	42	47	51	52	52	59	25	37	48	58	73	89	227	362	520	650	694	939	1,118	1,268	1,422	1,564	1,829	1,972	2,146	2,155	2,345	2,635	3,258	3,665	3,902	4,322	4,639	4,637	4,535	4,770	5,095	5,298	5,255	5,580	5,997	6,320	6,734	7,094	7,676	7,153	8,206	8,601	7,822	7,628	6,592	5,718	4,127	2,975	2,773	1,215	1,229	943	834	851	0	616	661	510	0	0	0	0
Retained Earnings	-942,322	-915,447	-902,000	-890,508	-864,302	-838,256	-829,267	-793,752	-756,122	-722,800	-672,545	-625,535	-575,156	-619,930	-585,866	-556,340	-539,806	-463,326	-444,289	-428,388	-415,960	-401,367	-383,025	-367,318	-351,840	-348,508	-335,388	-332,989	-281,048	-272,715	-265,296	-262,020	-257,753	-253,690	-248,480	-247,747	-236,372	-231,453	-228,933	-224,916	-205,371	-213,451	-206,953	-213,037	-217,084	-214,147	-205,557	-207,203	-202,032	-192,488	-208,552	-212,684	-203,821	-195,009	-189,413	-195,384	-190,975	-185,626	-169,357	-155,336	-157,776	-176,810	-180,246	-172,955	-174,377	-165,421	-147,365	-127,380	-119,417	-117,835	-111,814	-101,147	-96,913	-87,424	-77,714	-72,096	-65,539	-54,816	-45,018	-42,303	-39,843	-32,006	-27,450	-26,214	-20,525	-17,495	-20,915	-21,881	0	0	-20,106	-18,108	-15,013	-12,899	-10,737	-9,143	-7,718	-6,927	-5,888	-6,036	-5,502
Retained Earnings Total Equity	0	0	-902,000	-890,508	0	-838,256	-829,267	-793,752	-756,122	-722,800	-672,545	-625,535	-575,156	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Short Long Term Debt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	106	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,241	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Short Long Term Debt Total	97,607	93,214	101,206	7,931	8,088	8,188	8,384	8,571	8,739	8,906	8,936	8,881	8,407	8,298	6,202	5,851	0	378	412	421	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8	23	28	36	49	58	70	79	0	0	0	0	441	0	0	0	0	57	3,571	12,929	12,856	12,970	278	614	1,050	1,473	1,904	2,334	2,764	3,179	3,580	3,964	3,831	4,173	4,526	4,871	4,187	324	374	425	479	556	299	260	290	338	361	0	0	66	81	94	106	179	200	138	136	201	1,017	530
Short Term Debt	15,598	14,308	14,970	945	936	918	953	1,009	1,059	1,111	1,112	1,075	788	0	0	0	6,906	125	122	106	-118	0	0	0	4,068	0	0	0	2,928	0	0	0	0	0	0	0	0	0	0	0	1,317	8	23	28	36	49	46	46	44	0	0	0	0	128	0	0	0	0	14	1,680	4,750	3,532	2,478	237	532	928	1,313	1,625	1,722	1,715	1,407	1,672	1,625	1,477	1,441	1,326	1,403	959	168	188	187	240	245	187	131	132	136	136	0	0	35	40	44	48	105	133	69	68	67	949	464
Short Term Investments	301,614	291,503	269,006	272,533	295,218	290,592	240,104	286,210	234,178	228,813	197,176	191,668	125,979	143,284	31,936	11,913	0	0	0	3,975	7,889	23,985	17,899	27,905	7,833	94,860	10,071	3,050	0	3,047	2,999	7,040	9,997	9,989	10,008	9,999	9,998	9,994	0	0	0	0	0	0	0	0	0	857	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3,338	4,786	6,614	8,729	13,898	19,908	23,839	28,780	31,881	27,334	30,726	35,206	32,764	28,588	37,923	35,226	22,931	22,595	21,971	20,931	5,396	2,795	2,658	2,663	0	10,223	6,461	6,659	6,471	0	0	0	0	0	1,085	0
Temporary Equity Redeemable Noncontrolling Interests	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Assets	548,062	555,013	548,900	451,761	470,860	488,293	482,148	506,902	543,367	360,066	386,268	417,078	463,661	461,750	295,278	314,972	326,683	150,844	151,237	164,501	145,863	157,695	167,855	176,410	189,847	199,832	207,800	219,694	56,997	33,250	30,186	27,749	33,567	38,943	44,383	48,008	52,378	56,395	60,179	63,276	23,142	23,328	3,874	3,644	4,160	7,740	9,004	9,739	14,321	20,124	19,336	15,136	10,282	12,535	8,054	9,621	9,547	10,810	10,638	13,313	26,658	33,342	39,117	30,523	42,667	47,975	53,822	56,637	30,637	38,925	44,800	47,806	54,350	60,546	46,236	53,163	61,173	65,205	64,237	70,545	74,434	75,992	66,565	49,709	50,679	53,050	53,859	38,123	37,062	30,155	30,596	11,132	12,217	13,968	12,164	12,547	4,824	4,143	1,873	2,645	2,585
Total Current Assets	424,800	426,469	415,907	423,648	442,539	459,702	453,193	477,618	513,324	329,219	349,689	372,246	419,427	411,640	278,019	297,897	315,137	138,638	138,523	151,424	132,848	144,047	153,799	161,982	175,252	184,885	192,491	204,475	41,418	17,323	13,901	11,102	16,534	21,406	26,285	29,569	33,551	37,181	40,613	43,527	2,094	4,756	680	261	444	3,537	4,910	5,371	8,317	11,755	11,737	10,559	6,579	9,153	4,546	5,597	5,404	6,536	6,506	8,885	21,747	27,206	32,482	23,723	35,323	40,383	46,613	49,740	23,632	31,600	37,272	40,481	46,854	52,846	38,100	44,628	52,286	55,682	55,467	60,596	64,112	66,566	57,435	41,784	43,829	47,659	49,796	34,467	0	0	28,526	9,485	10,758	12,593	10,987	11,212	3,653	3,056	803	1,696	1,657
Total Current Liabilities	77,188	73,890	61,661	42,046	46,107	41,765	34,626	33,838	40,646	37,537	29,315	21,151	31,997	23,889	17,143	14,178	11,295	13,515	7,300	6,496	7,261	6,884	5,076	5,311	8,150	6,855	3,627	8,316	7,930	4,766	3,921	3,642	3,617	3,965	3,723	2,397	2,836	2,655	4,734	4,487	6,042	6,948	4,471	4,103	3,672	3,323	3,008	1,224	2,126	1,568	2,136	2,775	1,344	2,960	1,534	2,380	3,245	3,273	2,551	5,455	9,130	9,343	7,570	4,600	10,741	7,655	9,317	6,980	6,930	7,055	6,652	7,934	9,545	6,340	4,115	3,816	5,266	4,403	2,798	5,126	5,361	3,794	3,493	2,936	2,991	2,977	4,027	1,730	1,722	3,950	4,008	1,083	834	1,152	744	868	620	883	803	1,763	1,657
Total Liab	170,108	163,136	156,608	61,353	65,425	64,868	58,380	58,779	64,276	61,894	54,011	46,850	55,911	62,907	56,239	51,564	53,167	27,103	25,369	25,156	33,288	32,353	25,685	23,956	24,104	32,188	29,335	47,031	21,047	13,147	10,647	11,724	13,604	15,405	16,370	20,449	7,272	7,079	9,106	8,655	9,842	11,098	6,768	6,565	6,278	5,532	5,232	3,582	7,910	7,655	8,518	9,228	3,934	4,447	2,824	3,850	4,739	4,734	3,529	8,991	18,788	19,766	21,391	7,936	14,252	11,202	12,674	10,213	10,470	11,132	10,731	9,937	11,992	8,882	7,045	7,234	8,973	7,877	3,203	5,583	5,891	4,034	3,804	3,049	3,120	3,135	4,228	1,954	1,780	3,981	4,039	1,124	884	1,210	818	1,001	758	951	1,004	1,831	1,724
Total Permanent Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Stockholder Equity	377,954	391,877	392,292	390,408	405,435	423,425	423,768	448,123	479,091	298,172	332,257	370,228	407,750	398,843	239,039	263,408	273,516	123,741	125,868	139,345	112,575	125,342	142,170	152,454	165,743	167,644	178,465	172,663	35,950	20,103	19,539	16,025	19,963	23,538	28,013	27,559	45,106	49,316	51,073	54,621	13,301	12,231	-2,894	-2,921	-2,119	2,208	3,772	6,157	6,411	12,469	10,818	5,908	6,348	8,089	5,230	5,771	4,809	6,076	7,109	4,322	7,870	13,576	17,725	22,586	28,415	36,774	41,148	46,423	20,166	27,793	34,068	37,869	42,357	51,664	39,191	45,929	52,199	57,328	61,034	64,962	68,543	71,958	62,761	46,660	47,559	49,915	49,631	36,168	35,283	26,174	26,557	10,008	11,333	12,759	11,346	11,546	4,066	3,192	870	814	862
Treasury Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Warrants	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Cash Flow

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31	2001-12-31	2000-12-31	1999-12-31	1998-12-31
Begin Period Cash Flow	94,172	231,900	272,350	306,019	117,967	165,629	39,649	5,756	22,706	1,821	173	6,079	6,218	4,798	24,545	26,315	15,727	16,646	15,403	29,799	24,100	31,148	5,131	2,448	-136	130
Capital Expenditures	718	292	1,501	7,343	104	75	25	25	50	90	104	39	1,151	85	232	337	867	1,222	730	870	2,260	4,624	775	603	0	130
Cash And Cash Equivalents Changes	0	0	-40,450	-33,669	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash Flows Other Operating	0	0	5,350	12,277	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change In Cash	-45,297	-137,728	-40,450	-33,669	188,052	-47,662	125,980	33,893	-16,950	20,885	1,646	-5,894	-295	1,550	-19,962	-5,196	16,612	-3,284	1,303	-14,918	3,524	-11,297	25,671	2,873	2,716	-260
Change In Working Capital	-5,608	-6,817	-21,633	4,520	2,129	-6,000	1,699	1,470	1,221	-2,230	951	2,743	-318	-922	-1,852	-2,900	3,239	-474	4,439	-2,152	4,068	-1,147	-162	83	-340	195
Change Receivables	0	0	-15,415	-650	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Account Receivables	-10,606	1,927	-15,415	-13,620	-151	-108	-23	-39	45	9	66	103	-167	404	-263	-9	0	0	0	0	2,419	0	0	4	0	0
Change To Inventory	-15,869	-9,072	-5,644	-13,927	-3,855	-13,927	-13,927	0	0	0	0	0	0	0	139	1,514	-1,706	11	356	2	66	36	-8	-222	-204	0
Change To Liabilities	0	3,747	4,076	13,620	4,006	-887	2,168	2,458	869	-308	1,418	2,523	0	0	0	0	4,413	0	941	0	1,631	360	587	393	0	0
Change To Netincome	0	32,762	42,146	20,131	21,600	6,154	28,618	978	-1,938	2,373	-3,388	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Operating Activities	0	-3,419	-4,650	4,827	-1,977	-5,112	-2,596	-949	307	-1,931	-509	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	11,647	2,706	2,761	1,371	1,548	1,565	1,456	1,479	1,558	1,521	813	851	961	1,147	1,275	1,402	1,417	-867	1,971	2,251	1,336	681	331	411	204	260
Dividends Paid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
End Period Cash Flow	48,875	94,172	231,900	272,350	306,019	117,967	165,629	39,649	5,756	22,706	1,819	185	5,924	6,348	4,583	21,118	32,339	13,361	16,706	14,881	27,624	19,851	30,803	5,321	2,581	-130
Exchange Rate Changes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Free Cash Flow	-34,179	-79,821	-159,193	-77,201	-63,560	-51,685	-41,194	-18,738	-17,816	-16,994	-4,627	-6,586	-2,506	-4,423	-10,689	-17,727	-29,327	-22,252	-21,961	-21,021	-7,395	-5,474	-8,021	-6,369	-1,358	-1,888
Investments	-3,467	-60,632	-84,531	-150,843	7,780	-66	-8,003	9,991	27	-9,994	-9,408	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Issuance Of Capital Stock	0	0	196,740	187,732	223,118	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Borrowings	0	0	0	0	-127	-127	-127	-127	0	-1,600	335	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	-78,020	-108,180	-180,966	-102,680	-123,846	-64,120	-70,792	-23,295	-18,607	-16,647	-2,546	-9,737	-2,407	-5,560	-7,598	-15,882	-33,822	-22,853	-29,075	-22,560	-14,646	-366	-7,405	-6,285	-1,222	-2,214
Other Cashflows From Financing Activities	-10,025	2,433	24,372	6,643	20,737	4,014	175,152	42,615	839	1,183	378	-31	-1,151	4,614	5,805	10,692	-1,888	-1,577	-977	4,740	-284	130	26	-83	-1,087	716
Other Cashflows From Investing Activities	0	-663	-11,838	-7,343	-1,675	-1,675	-1,675	10,016	27	-28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Non Cash Items	74,895	462	10,903	9,477	8,152	118	-1,766	2,001	-36	1,104	-109	-4,809	4,483	997	-2,282	40	706	3,163	1,434	2,310	4,108	-18	-11	25	0	-65
Sale Purchase Of Stock	0	0	221,112	194,375	243,855	4,014	175,152	2,012	839	49,490	5,666	0	0	0	0	0	0	0	0	0	-641	-205	0	0	0	0
Stock Based Compensation	45,311	32,300	31,243	17,454	7,414	6,860	4,242	1,383	3,224	2,186	224	276	371	0	0	490	0	0	0	0	0	0	0	0	0	0
Total Cash From Financing Activities	-5,130	2,433	221,112	194,375	243,728	4,014	175,152	42,615	839	47,890	6,205	717	2,282	4,643	-9,611	10,323	36,032	-1,272	15,261	4,865	24,618	12,376	30,409	15,892	4,210	1,563
Total Cash From Operating Activities	-33,461	-79,529	-157,692	-69,858	-63,456	-51,610	-41,169	-18,713	-17,766	-16,904	-4,523	-6,547	-1,356	-4,338	-10,456	-17,390	-28,460	-21,030	-21,230	-20,151	-5,134	-850	-7,246	-5,766	-1,358	-1,758
Total Cashflows From Investing Activities	0	-60,632	-103,870	-158,186	7,783	-65	-8,003	9,991	-23	-10,080	-34	0	0	0	0	0	9,171	19,015	7,302	979	0	0	2,508	0	0	0

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31	2002-09-30	2002-06-30	2002-03-31	2001-12-31	2001-09-30	2001-06-30	2001-03-31	2000-12-31	2000-09-30	2000-06-30	2000-03-31	1999-12-31	1999-09-30	1999-06-30	1999-03-31	1998-12-31
Begin Period Cash Flow	46,397	81,707	89,001	94,172	86,052	151,632	132,542	231,900	57,587	121,561	156,591	272,350	248,758	232,414	274,207	306,019	134,539	131,493	140,359	117,967	114,898	132,302	131,227	165,629	87,546	179,717	199,066	39,649	12,333	9,125	3,492	5,756	10,594	15,728	19,042	22,706	25,533	39,093	43,289	1,821	4,502	463	32	181	289	1,395	3,282	6,062	7,333	8,643	10,173	6,532	7,002	3,981	5,069	4,708	5,848	6,314	4,619	20,354	26,491	29,787	20,808	31,113	35,849	40,374	41,518	13,500	15,673	15,074	14,685	16,643	19,332	9,229	12,277	14,788	21,453	25,107	21,251	27,320	42,291	33,210	17,340	21,292	39,452	41,565	30,379	30,746	0	16,789	1,912	9,511	11,781	10,336	10,545	2,894	2,619	134	814	1,193	-133
Capital Expenditures	50	105	227	509	79	38	39	79	35	63	222	1,181	2,183	2,364	131	106	32	30	22	20	22	8	31	22	9	16	12	4	17	4	3	1	6	18	22	10	21	21	47	1	17	36	46	6	10	11	9	9	85	0	29	1,091	21	28	18	18	67	104	28	32	98	58	103	78	291	264	118	194	342	590	61	228	613	13	48	55	121	506	92	151	208	533	808	711	1,324	1,307	306	1,687	774	611	400	138	81	318	18	198	69	0	0	0	0
Cash And Cash Equivalents Changes	0	0	-7,294	-5,171	0	-65,580	19,090	-99,358	174,313	-63,974	-35,030	-115,759	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash Flows Other Operating	0	0	-1,277	3,509	0	944	-6,076	290	1,188	5,517	-2,094	739	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change In Cash	2,478	-35,310	-7,294	-5,171	8,120	-65,580	19,090	-99,358	174,313	-63,974	-35,030	-115,759	23,592	16,344	-41,793	-31,812	171,480	3,046	-8,866	22,392	3,069	-17,404	1,075	-34,402	78,083	-92,171	-19,349	159,417	27,316	3,208	5,633	-2,264	-4,838	-5,134	-3,314	-3,664	-2,827	-13,560	-4,196	41,468	-2,683	4,038	422	-147	-104	-1,106	-1,932	-2,716	-1,409	-1,311	-1,530	3,640	-654	3,022	-1,088	361	-1,265	-466	1,695	-15,735	-5,372	-3,296	8,978	-10,305	-3,510	-4,525	-1,144	28,018	-2,311	599	388	-1,957	-2,626	10,103	-3,048	-2,511	-6,572	-3,655	3,856	-6,068	-14,667	9,081	15,869	-3,952	-19,601	-2,112	11,186	-367	0	0	14,877	-7,599	-2,271	-5,015	-209	7,650	276	2,447	-680	-379	1,326
Change In Working Capital	19,587	-13,904	2,119	-13,254	31,964	-16,042	-4,248	-18,491	-1,763	-11,679	1,369	-9,560	-3,018	6,708	-662	-1,425	-7,014	9,263	849	-969	-1,151	242	-983	-4,108	1,983	3,450	-3,485	-249	3,033	304	-894	-973	-101	137	1,305	-120	988	-495	-114	-2,510	-959	852	505	549	4,175	471	-582	-1,284	199	-480	324	-361	60	-239	-315	-428	157	222	-2,046	-185	604	1,129	870	-5,503	1,676	-1,260	2,539	283	1,023	-1,608	1,253	-1,142	3,349	1,983	298	-1,190	-109	501	-2,190	-353	1,640	593	1,359	476	-1,051	1,585	-1,715	34	0	0	2,531	387	-758	323	-107	280	-413	196	-128	-341	-66
Change Receivables	0	0	-457	-5,559	0	-23,598	2,228	-4,986	-5,600	-5,397	-3,231	-1,187	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Account Receivables	14,056	-18,447	-457	-5,559	28,283	-23,598	2,228	-4,986	-5,600	-5,397	-3,231	-1,187	-1,018	-1,187	-1,187	368	102	-222	128	-159	542	-452	-82	-116	306	-130	-162	-37	12	-49	-2	0	8	30	29	-22	-43	64	1	1	-33	104	-1	-4	25	164	591	-688	-58	-5	6	-111	2	27	130	245	-215	-370	180	142	0	184	77	3	0	169	79	0	0	69	59	21	0	0	0	6	0	0	0	0	2,419	0	0	0	0	0	0	0	0	0	0	0	4	0	0	0	0	0	0	0	0
Change To Inventory	-6,704	-581	-1,410	-6,993	-614	-505	-1,013	-6,940	-278	-1,917	-1,440	-2,009	-13,456	-471	-471	-471	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-23	-2,672	0	0	0	0	0	0	0	0	0	3	11	191	-66	-155	1,621	13	34	-1,565	-118	-104	81	58	-30	0	0	286	70	0	0	2	0	0	0	66	0	0	0	36	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Liabilities	0	0	5,362	-4,117	2,872	7,117	462	-6,704	2,927	118	7,103	-7,103	4,608	6,548	1,230	1,234	-1,995	6,183	789	-871	377	1,808	-235	-2,838	2,168	874	-2,693	341	2,458	0	0	0	869	1,153	887	0	-308	0	0	0	1,418	1,759	1,018	524	2,523	2,179	1,893	58	0	0	81	0	0	0	0	0	0	0	0	0	0	0	0	0	4,413	950	2,608	333	0	0	0	0	941	0	0	0	0	0	0	0	1,631	0	0	0	360	0	0	0	587	0	0	0	393	0	0	0	0	0	0	0	0
Change To Netincome	0	0	8,816	9,684	4,313	8,860	11,052	8,537	8,475	11,001	-5,710	5,710	13,886	11,102	7,101	-5,158	57,924	-2,390	1,414	-135	1,775	6,365	3,998	4,807	28,618	783	-6,334	42,112	978	0	0	0	-1,938	0	0	0	2,373	0	0	0	-3,388	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Operating Activities	0	0	-1,376	-1,376	1,423	944	-5,925	139	1,188	-4,483	-739	739	5,830	3,548	-1,892	-2,659	-5,221	3,302	-68	-98	-2,070	-1,114	-666	-1,154	-2,596	354	-630	-553	-949	0	0	0	307	0	0	0	-1,931	0	0	0	-509	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	4,949	5,262	719	717	219	809	840	838	688	683	702	688	410	502	493	403	391	389	385	383	355	408	403	399	361	362	370	363	365	362	365	387	363	434	363	398	410	373	369	369	575	79	78	82	201	216	210	213	268	198	252	243	262	243	394	248	306	363	268	338	552	158	352	340	562	380	346	129	-43	196	-295	-726	538	670	397	366	718	471	698	365	466	316	306	249	301	106	181	93	0	0	77	70	40	111	167	65	69	70	66	2	66
Dividends Paid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
End Period Cash Flow	48,875	46,397	81,707	89,001	94,172	86,052	151,632	132,542	231,900	57,587	121,561	156,591	272,350	248,758	232,414	274,207	306,019	134,539	131,493	140,359	117,967	114,898	132,302	131,227	165,629	87,546	179,717	199,066	39,649	12,333	9,125	3,492	5,756	10,594	15,728	19,042	22,706	25,533	39,093	43,289	1,819	4,502	454	33	185	289	1,350	3,346	5,924	7,333	8,643	10,173	6,348	7,002	3,981	5,069	4,583	5,848	6,314	4,619	21,118	26,491	29,787	20,808	32,339	35,849	40,374	41,518	13,361	15,673	15,074	14,685	16,706	19,332	9,229	12,277	14,881	21,453	25,107	21,251	27,624	42,291	33,210	17,340	19,851	39,452	41,565	30,379	30,746	0	16,789	1,912	9,511	5,321	10,336	10,545	2,894	2,581	134	814	1,193
Exchange Rate Changes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Free Cash Flow	14,766	-13,172	-3,053	-32,179	10,529	-15,400	-27,910	-46,825	-25,957	-40,313	-38,201	-54,722	1,021	-32,644	-22,725	-22,820	-25,311	-11,805	-13,275	-13,169	-13,636	-11,327	-12,320	-14,402	-11,090	-8,525	-11,860	-9,719	-4,277	-4,192	-5,048	-5,221	-4,838	-5,216	-3,719	-4,032	-3,365	-4,045	-4,230	-5,355	-2,469	-1,531	-416	-205	-789	-1,103	-2,757	-1,820	-1,327	-1,213	-1,521	1,501	-2,298	-57	-2,440	372	-1,546	-1,643	-4,257	-3,243	-1,506	-1,995	-4,229	-9,998	-6,506	-9,639	-6,938	-6,245	-5,667	-5,191	-4,720	-6,674	-5,774	-3,367	-5,943	-6,876	-7,361	-6,015	-4,541	-3,104	-1,275	-4,209	2,126	-4,036	-4,822	2,847	147	-3,646	0	0	104	-2,793	-2,924	-2,314	-1,453	-1,431	-1,172	-689	9	-744	66
Investments	-6,257	-19,701	6,483	25,369	-3,018	-49,797	45,660	-52,938	-5,452	-32,743	54,228	-54,228	16,893	-142,633	-20,154	-12,019	-32	-30	3,952	3,890	16,093	-6,085	10,001	-20,000	-7,978	-84,889	-7,013	-3,044	9,997	0	0	0	27	0	0	0	-9,994	0	0	0	-9,408	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Issuance Of Capital Stock	0	0	0	0	0	0	0	0	196,740	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Borrowings	0	0	268	263	0	325	291	281	0	67	128	0	0	0	0	0	-38	-37	-29	-23	-23	-23	-23	0	0	0	0	0	0	0	0	0	0	0	0	0	-1,600	0	0	0	335	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	-26,875	-13,447	-11,492	-26,206	-26,046	-8,989	-35,515	-37,630	-33,322	-50,255	-47,010	-50,379	-8,074	-34,064	-29,526	-16,534	-76,480	-19,037	-15,901	-12,428	-14,593	-18,342	-15,707	-15,478	-3,332	-13,120	-2,399	-51,941	-8,333	-7,419	-3,276	-4,267	-4,063	-5,210	-733	-8,601	-4,919	-2,520	-4,017	-5,191	1,555	-2,369	-944	-779	-5,166	-1,729	-2,304	-455	-6,332	2,035	4,866	-2,977	-2,517	-1,535	-592	-916	-1,609	-2,026	-693	-3,270	-2,199	-3,103	-5,395	-5,185	-8,602	-8,613	-9,885	-6,722	-5,819	-6,239	-6,196	-4,599	-9,416	-6,259	-6,433	-6,967	-8,710	-7,587	-3,363	-2,900	-6,758	-4,612	773	-4,050	-2,776	2,494	1,990	-2,073	0	0	-2,099	-3,103	-2,125	-2,441	-1,508	-1,578	-758	-888	72	-473	66
Other Cashflows From Financing Activities	105	-3,489	-10	1,639	-1,745	-50,218	1,340	-53,017	8,982	-32,806	1,670	-67,247	19,146	1,525	-20,154	-12,019	196,829	14,888	464	31,674	16,071	-6,085	9,970	-20,022	86,959	-84,889	1,674	9,856	28,540	1,293	-440	2,956	-195	8	-31	-11	4,235	-10,013	-47	-3,563	-10	0	380	60	762	-3	826	-860	-12	53	-29	-1,091	65	4,549	1,468	-17	118	443	5,243	-3,538	-1,524	-630	-101	-75	-439	-523	-488	-438	-340	-411	-442	-383	123	-402	2,972	4,636	843	3,986	-44	-46	-461	-76	232	20	-237	-41	-30	233	0	0	-13	-13	-12	-64	-19	-263	-138	-2	-134	57	-464
Other Cashflows From Investing Activities	0	0	-12,091	-509	-282	-421	-39	-79	11,838	-63	11,838	-13,019	-1,675	-1,675	-1,675	-1,675	7,884	7,884	7,884	3,910	9	0	0	0	0	0	0	0	9	0	0	0	-44	0	0	0	-28	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	209	95	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Non Cash Items	18,289	-675	-841	-2,394	-2,589	540	997	1,514	-102	13,909	-793	-2,111	8,741	-8,037	2,899	-8,654	55,996	-4,412	-546	-1,739	561	4,859	1,969	2,696	-11,048	-285	-7,312	40,871	319	2,017	-1,390	-696	-1,525	-1,238	-5,405	3,017	10	-1,668	-856	680	-3,637	-86	-86	-155	-137	-89	-109	-337	4,485	-3,176	-6,946	5,676	-82	1,368	-2,001	1,434	-332	-98	-1,797	-101	-365	-120	47	427	150	118	179	258	-486	3,050	578	21	368	253	-157	970	862	1,106	407	-65	3,584	27	497	0	28	-31	-2	-13	0	0	-4	-8	0	12	14	0	0	-67	-1	68	0
Sale Purchase Of Stock	0	0	1,140	1,639	0	0	1,340	405	205,722	9,082	1,279	5,029	0	0	0	2,921	243,855	47,026	32,138	31,674	4,014	0	0	0	177,248	1,243	1,655	163,515	42,810	0	0	0	839	0	0	0	49,490	0	0	0	5,666	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-139	-83	-81	-337	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Stock Based Compensation	11,768	11,808	12,268	9,467	6,902	8,320	10,055	7,023	8,577	7,092	7,753	7,821	5,145	4,611	4,202	3,496	1,828	2,022	1,960	1,604	1,214	1,506	2,029	2,111	955	1,068	978	1,241	356	548	150	329	488	679	773	1,284	167	286	435	1,298	13	29	77	104	148	39	36	51	138	210	12	10	0	134	92	51	0	0	39	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Cash From Financing Activities	-5,532	-2,332	1,140	1,639	688	-24	1,340	405	205,722	9,082	1,279	5,029	1,242	189,257	955	2,921	196,791	14,851	435	31,651	612	8	3,394	3,394	2,205	1,243	-476	172,180	28,540	7,435	6,640	0	839	56	414	369	542	477	34	46,837	-205	5,563	838	-8	750	-11	-11	-11	25	-161	8	2,410	67	4,560	16	0	-196	-754	926	-9,587	-1,545	-637	12,830	-325	-343	2,025	2,292	32,059	-335	-412	-374	-152	153	15,469	-13	-348	896	4,010	-39	-2	465	13,920	10,513	-280	102	-605	9,622	3,256	30,409	20,900	18,735	1,773	698	3,920	1,159	9,227	1,585	3,073	-558	436	1,260
Total Cash From Operating Activities	14,816	-13,277	-2,826	-31,670	10,450	-15,362	-27,871	-46,746	-25,922	-40,250	-37,979	-53,541	3,204	-30,280	-22,594	-22,714	-25,279	-11,775	-13,253	-13,149	-13,614	-11,327	-12,289	-14,380	-11,081	-8,525	-11,848	-9,715	-4,260	-4,188	-5,045	-5,220	-4,838	-5,198	-3,697	-4,022	-3,344	-4,024	-4,183	-5,354	-2,452	-1,495	-371	-200	-779	-1,092	-2,748	-1,811	-1,242	-1,213	-1,492	2,592	-2,277	-29	-2,422	389	-1,478	-1,539	-4,229	-3,211	-1,408	-1,936	-4,126	-9,920	-6,215	-9,374	-6,820	-6,051	-5,325	-4,601	-4,659	-6,445	-5,161	-3,354	-5,895	-6,821	-7,240	-5,509	-4,449	-2,953	-1,067	-3,676	2,934	-3,325	-3,498	4,154	453	-1,959	0	0	504	-2,654	-2,843	-1,996	-1,434	-1,233	-1,103	-689	9	-744	66
Total Cashflows From Investing Activities	0	0	-5,608	24,860	-3,018	-50,218	45,621	-53,017	-5,487	-32,806	67,247	-67,247	19,146	-145,159	-20,154	-12,019	-32	-30	3,952	3,890	16,071	-6,085	9,970	-20,022	-8,003	-84,889	-7,025	-3,048	9,991	6,955	6,994	2,956	-23	0	0	0	-10,080	0	0	0	-34	0	12	60	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	9,171	6,152	4,359	2,012	19,015	14,971	9,287	4,626	7,302	4,920	7,605	4,637	979	2,074	5,648	0	0	0	166	0	0	0	0	0	2,508	0	0	0	0	0	0	0	0	0	0	0	0

Income Statement

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2003-12-31	2002-12-31	2001-12-31	2000-12-31	1999-12-31	1998-12-31
Cost Of Revenue	14,148	5,664	1,091	50,327	52,866	41,382	1	4	12	37	1	46	185	51	576	2,115	1,050	597	2,062	1,603	1,455	686	1,025	681	679	521
Depreciation And Amortization	11,647	2,706	2,098	8,098	1,548	1,565	1,456	1,479	1,558	1,521	813	851	961	1,147	1,275	1,402	1,417	-867	1,971	2,251	1,336	681	331	411	204	260
Discontinued Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ebit	-83,312	-111,470	-180,735	-104,290	-82,539	-46,204	-23,139	-22,306	-28,503	-17,217	-4,028	-5,506	-2,406	-5,459	-9,017	-15,619	-35,678	-21,735	-30,124	-23,083	-11,165	-1,543	-7,530	-6,740	-1,222	-2,669
Ebitda	-71,665	-108,764	-178,637	-96,192	-80,991	-44,639	-21,683	-20,827	-26,945	-15,696	-3,215	-4,655	-1,446	-4,312	-7,742	-14,217	-34,261	-22,602	-28,153	-20,832	-9,829	-862	-7,199	-6,329	-1,019	-2,409
Effect Of Accounting Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Extraordinary Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Gross Profit	161,365	128,366	44,514	-209	-52,548	-40,919	419	169	223	241	948	6,112	742	3,369	3,476	1,762	1,284	2,926	1,178	1,274	7,661	11,231	4,272	222	679	260
Income Before Tax	-77,469	-106,352	-180,206	-102,774	-123,702	-64,047	-70,792	-23,295	-18,607	-16,647	-6,402	-9,738	-2,407	-5,459	-7,598	-15,882	-33,822	-22,853	-29,074	-22,556	-14,520	-294	-7,349	-6,271	0	-2,344
Income Tax Expense	551	1,828	760	-94	144	73	23,924	481	-4,973	30	-3,856	55	4,024	101	1,029	741	350	-1	1	3	126	72	55	14	0	-130
Interest Expense	2,775	5,118	529	5,293	39	2,234	702	27	50	30	100	56	1	12	1,029	741	0	269	381	0	35	0	0	15	0	0
Interest Income	15,338	5,118	529	1,516	2,702	2,234	1,040	27	5,310	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	-78,020	-108,180	-180,966	-102,680	-123,846	-64,120	-70,792	-23,295	-18,607	-16,647	-2,546	-9,737	-2,407	-3,660	-7,598	-15,882	-33,822	-22,853	-29,075	-22,560	-14,646	-366	-7,405	-6,285	-1,222	-2,214
Net Income Applicable To Common Shares	0	-108,180	-180,966	-102,680	-88,385	-53,079	-70,792	-23,295	-18,607	-19,421	-2,506	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income From Continuing Ops	-77,191	-108,180	-180,966	-102,680	-123,846	-64,120	-70,792	-23,295	-18,607	-19,421	-2,506	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Interest Income	13,873	5,118	529	1,516	2,663	2,234	702	27	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Operating Income Net Other	0	0	529	1,516	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Recurring	0	0	0	0	0	0	0	0	0	1,068	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Operating Income	-83,312	-111,470	-180,735	-104,290	-82,539	-56,158	-47,063	-22,814	-23,580	-17,282	-5,505	-5,468	-6,439	-5,046	-10,046	-16,360	-36,024	-24,153	-30,289	-23,159	-11,217	-1,543	-7,530	-6,740	-1,222	-2,669
Other Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Operating Expenses	258,825	245,500	226,340	147,599	76,568	56,621	47,483	22,987	23,815	17,560	4,979	11,626	7,366	8,467	13,069	19,495	38,359	27,676	31,467	24,432	18,878	13,460	12,827	7,643	2,581	3,451
Preferred Stock And Other Adjustments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Reconciled Depreciation	6,917	2,706	2,761	1,371	1,548	1,565	1,456	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Research Development	49,641	44,988	51,139	50,327	52,866	41,382	33,930	14,534	15,982	9,112	1,934	5,509	3,476	3,989	7,652	11,443	29,697	19,004	19,445	13,520	9,123	7,106	8,410	4,778	1,426	1,432
Selling And Marketing Expenses	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Selling General Administrative	195,036	196,371	171,438	95,983	22,154	13,674	12,096	6,970	6,263	6,890	2,231	3,902	2,744	3,267	3,610	4,539	5,711	6,193	9,783	7,850	8,332	4,966	3,053	1,773	1,019	1,367
Tax Provision	947	1,828	760	-94	144	73	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Operating Expenses	244,677	239,836	225,249	147,599	76,568	56,621	47,482	22,983	23,803	17,523	4,979	11,580	7,181	8,416	12,494	17,380	37,309	27,079	31,467	24,432	18,878	12,774	11,802	6,962	1,901	2,930
Total Other Income Expense Net	5,843	5,118	529	1,516	-41,163	-7,889	-23,729	-508	4,923	600	-2,274	-4,176	4,023	-425	2,448	478	2,206	1,238	1,494	33	-3,303	1,249	180	5	0	326
Total Revenue	175,513	134,030	45,605	50,118	318	463	420	173	235	278	949	6,158	928	3,420	4,052	3,877	2,335	3,523	1,178	1,274	7,661	11,917	5,297	903	1,358	781

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2003-12-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31	2002-09-30	2002-06-30	2002-03-31	2001-12-31	2001-09-30	2001-06-30	2001-03-31	2000-12-31	2000-09-30	2000-06-30	2000-03-31	1999-12-31	1999-09-30	1999-06-30	1999-03-31	1998-12-31
Cost Of Revenue	5,395	6,769	1,563	421	1,362	2,447	1,599	256	481	254	308	48	13,173	4,800	11,076	13,835	13,292	17,791	11,152	10,631	10,839	11,152	10,504	8,887	8,691	10,807	7,107	1	1	1	1	1	2	1	4	5	8	11	10	8	1	527	430	1	7	9	11	19	14	12	15	155	9	9	5	27	39	45	237	17	-156	1,806	227	254	370	288	163	186	165	159	128	140	354	176	129	226	210	181	728	363	264	277	731	126	118	194	239	135	197	167	170	377	289	218	198	67	207	77	201	136	265
Depreciation And Amortization	4,949	5,262	719	717	219	809	840	838	522	683	702	688	387	502	493	403	391	389	385	383	355	408	403	399	361	362	370	363	365	362	365	387	363	434	363	398	410	373	369	369	575	79	78	82	201	216	210	213	268	198	252	243	262	243	394	248	306	363	268	338	552	158	352	340	562	380	346	129	-43	196	-295	-726	538	670	397	366	718	471	698	365	466	316	306	249	301	106	181	93	0	0	77	70	40	111	167	65	69	70	66	2	66
Discontinued Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ebit	-20,600	-11,749	-12,069	-30,301	-28,319	-9,499	-35,989	-37,882	-32,705	-50,353	-47,134	-48,772	-2,309	-36,471	-26,474	-24,978	-28,384	-23,375	-16,387	-14,074	-14,070	-9,183	-12,341	-10,376	-21,143	-14,061	-17,280	29,847	-7,710	-3,354	-5,823	-5,419	-10,361	-6,362	-6,039	-5,560	-4,824	-4,134	-4,546	-3,713	-1,364	-1,018	-903	-817	-5,689	-1,690	-1,909	3,789	2,159	-1,075	-1,906	-1,793	-2,514	-1,400	-605	-930	-1,689	-1,749	-2,321	-2,590	-1,450	-3,616	-5,571	-5,182	-9,126	-8,158	-9,746	-6,830	-5,765	-6,395	-5,514	-3,791	-9,450	-5,651	-6,963	-7,303	-8,689	-6,676	-3,991	-3,391	-5,261	-4,137	1,766	-3,235	-3,093	1,746	2,291	-2,362	0	0	-2,142	-3,253	-2,276	-2,616	-1,593	-1,733	-827	-553	67	-407	-199
Ebitda	-15,651	-6,487	-11,350	-29,584	-28,100	-8,690	-35,149	-37,044	-32,183	-49,670	-46,432	-48,084	-1,922	-35,969	-25,981	-24,575	-27,993	-22,986	-16,002	-13,691	-13,715	-8,775	-11,938	-9,977	-20,782	-13,699	-16,910	30,210	-7,345	-2,992	-5,458	-5,032	-9,998	-5,928	-5,676	-5,162	-4,414	-3,761	-4,177	-3,344	-789	-938	-825	-735	-5,488	-1,473	-1,699	4,002	2,427	-877	-1,654	-1,551	-2,252	-1,158	-211	-682	-1,383	-1,386	-2,052	-2,252	-898	-3,457	-5,219	-4,842	-8,564	-7,778	-9,400	-6,701	-5,807	-6,199	-5,809	-4,517	-8,912	-4,981	-6,566	-6,937	-7,971	-6,205	-3,294	-3,026	-4,795	-3,821	2,072	-2,987	-2,792	1,852	2,472	-2,269	0	0	-2,066	-3,182	-2,236	-2,505	-1,426	-1,669	-758	-483	133	-405	-133
Effect Of Accounting Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Extraordinary Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Gross Profit	39,700	47,746	39,931	33,988	27,073	53,332	26,592	21,369	22,923	14,413	6,312	866	36,857	-4,771	29	-13,805	-13,263	-17,561	-11,123	-10,601	-10,810	-10,777	-10,475	-8,857	31	29	329	30	29	30	54	56	55	56	55	57	60	61	61	59	692	84	83	86	80	78	78	5,794	106	523	137	-17	288	255	1,409	1,420	1,617	915	382	647	249	896	328	309	246	266	266	606	473	361	809	1,369	-1,131	1,763	204	317	255	262	255	468	616	307	6,529	216	183	3,995	5,218	2,068	3,379	0	353	146	159	82	52	0	69	411	0	136	133
Income Before Tax	-26,416	-13,149	-12,134	-25,770	-25,191	-8,035	-35,506	-37,620	-32,596	-50,247	-46,992	-50,371	-7,917	-34,099	-29,504	-16,770	-76,379	-19,012	-15,885	-12,415	-14,520	-18,342	-15,707	-15,478	-3,332	-13,120	-2,399	-51,941	-8,333	-7,419	-3,276	-4,267	-3,937	-5,155	-733	-8,601	-4,919	-2,520	-4,017	-5,191	-2,301	-2,369	-944	-779	-5,167	-1,729	-2,304	-418	-6,336	2,159	4,875	-2,979	-2,421	-1,505	-623	-916	-1,609	-1,685	-213	-2,595	-2,203	-3,511	-5,334	-5,177	-8,602	-7,413	-9,323	-6,675	-4,689	-6,678	-6,361	-4,900	-9,416	-5,254	-6,521	-6,865	-8,276	-7,554	-3,723	-2,890	-5,761	-4,994	902	-4,284	-7,331	3,796	5,854	-2,341	0	0	-2,139	-3,245	-2,275	-2,633	0	0	-758	0	67	-339	-66
Income Tax Expense	459	298	-642	436	855	954	9	10	726	8	18	8	157	-35	22	-236	90	25	16	13	73	4,234	1,367	2,431	-9,004	-670	-7,650	40,856	308	2,029	-1,276	-580	-4,847	55	0	0	0	0	0	30	-3,856	-217	45	25	-16	27	1	37	4,028	31	-1	-2	-382	4	-154	-1,697	21	0	194	675	736	149	2	12	0	0	18	292	1,480	-137	301	793	106	304	0	121	456	-324	-313	27	1,048	-368	-234	-234	-4,555	1,318	3,757	-268	55	0	2	-141	-150	-191	-147	-65	0	335	134	136	-133
Interest Expense	1,310	1,400	65	3,814	2,909	1,464	483	262	109	106	142	172	339	101	78	25	9	9	123	11	671	691	632	240	191	399	419	76	7	7	5	8	10	11	13	16	17	16	22	30	28	24	24	25	15	27	1	42	1	2	1	2	7	7	1	0	21	210	194	675	419	312	51	8	17	29	38	47	54	65	73	81	83	91	95	102	90	55	8	9	10	11	6	6	7	8	4	3	1	1	3	3	15	3	3	2	4	0	0	0	0
Interest Income	4,568	4,514	4,101	3,814	2,909	1,464	483	262	109	106	142	172	135	170	320	891	468	636	787	2,463	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	-26,875	-13,447	-11,492	-26,206	-26,046	-8,989	-35,515	-37,630	-33,322	-50,255	-47,010	-50,379	-8,074	-34,064	-29,526	-16,534	-76,469	-19,037	-15,901	-12,428	-14,593	-18,342	-15,707	-15,478	-3,332	-13,120	-2,399	-51,941	-8,333	-7,419	-3,276	-4,267	-3,937	-5,155	-733	-8,601	-4,919	-2,520	-4,017	-5,191	1,555	-2,152	-988	-779	-5,166	-1,729	-2,304	-455	-6,332	2,161	4,877	-2,977	-2,459	-1,502	-461	781	-1,609	-1,685	-407	-3,270	-2,199	-3,511	-5,336	-5,185	-8,602	-7,413	-9,323	-6,722	-5,819	-6,262	-5,983	-4,599	-9,416	-5,540	-6,521	-6,967	-8,710	-7,230	-3,411	-2,900	-6,758	-4,624	1,136	-4,050	-2,776	2,490	2,097	-2,073	0	0	-2,140	-3,104	-2,125	-2,441	-1,446	-1,669	-758	-888	67	-475	66
Net Income Applicable To Common Shares	0	0	-11,492	-26,206	-26,046	-8,989	-35,515	-37,630	-33,322	-50,255	-47,010	-50,379	-8,074	-42,130	-35,942	-16,534	-76,480	-19,037	-15,901	-12,428	-14,593	-18,342	-15,707	-15,478	-10,529	-161,746	153,424	-51,941	-23,295	0	0	0	-18,607	0	0	0	-22,169	2,748	0	0	1,431	0	0	0	0	0	0	0	-2,199	2,135	4,902	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-1,131	1,136	0	-2,513	2,490	2,097	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income From Continuing Ops	-26,875	-13,447	-11,492	-26,206	-26,046	-8,989	-35,515	-37,630	-33,322	-50,255	-47,010	-50,379	-8,074	-34,064	-29,526	-16,534	-76,480	-19,037	-15,901	-12,428	-14,593	-18,342	-15,707	-15,478	-10,529	-161,746	153,424	-51,941	-23,295	0	0	0	-18,607	0	0	0	-19,421	0	0	0	-2,506	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Interest Income	3,258	3,114	4,036	3,814	2,909	1,464	483	262	109	106	142	172	135	69	242	866	459	627	777	800	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Operating Income Net Other	0	0	0	0	0	0	0	0	215	0	142	172	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Recurring	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,068	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Operating Income	-20,600	-16,263	-16,170	-29,584	-28,100	-9,499	-35,989	-37,882	-32,705	-50,353	-47,134	-50,543	-8,052	-36,341	-26,863	-25,269	-20,900	-24,011	-16,454	-14,885	-14,663	-14,108	-14,340	-13,047	-12,139	-13,790	-10,049	-11,085	-8,025	-5,390	-4,552	-4,847	-5,524	-6,428	-6,052	-5,576	-4,841	-4,210	-4,568	-3,723	-1,349	-1,018	-903	-817	-5,644	-1,691	-1,910	3,789	-1,873	-1,108	-1,906	-1,793	-2,094	-1,407	-613	-930	-1,710	-1,749	-2,321	-2,590	-2,191	-3,765	-5,571	-5,186	-9,126	-8,158	-9,764	-7,075	-6,115	-6,674	-6,193	-4,886	-9,556	-5,668	-6,963	-7,322	-8,710	-6,676	-3,991	-3,408	-5,313	-4,139	1,766	-3,235	-3,093	1,733	2,291	-2,362	0	0	-2,143	-3,253	-2,276	-2,616	-1,612	-1,735	-827	-553	-67	-407	-199
Other Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Operating Expenses	65,695	70,778	57,664	63,993	56,535	65,278	64,180	59,507	56,109	65,020	53,754	49,686	52,339	36,370	27,110	25,299	20,929	24,241	16,483	14,915	14,692	14,483	14,369	13,077	12,170	13,819	10,378	11,116	8,055	5,421	4,607	4,904	5,581	6,485	6,111	5,638	4,909	4,222	4,639	3,790	2,060	1,102	986	904	5,730	1,778	1,999	2,025	1,993	1,643	2,059	1,931	2,399	1,664	2,026	2,378	3,345	2,708	2,939	3,237	1,543	6,468	6,126	5,749	9,742	8,712	10,194	7,681	6,753	7,193	7,130	6,255	8,426	7,431	7,167	7,640	8,966	6,939	4,246	3,876	5,928	4,446	4,763	3,451	3,393	2,455	3,165	4,565	0	0	2,666	3,775	2,724	2,915	1,861	1,802	1,103	1,042	268	678	597
Preferred Stock And Other Adjustments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Reconciled Depreciation	4,949	5,262	719	717	219	809	840	838	688	683	702	688	-27	502	493	403	391	389	385	383	355	408	403	399	361	362	370	363	365	362	365	387	363	434	363	398	410	373	369	369	575	79	78	82	201	216	210	213	268	198	252	243	262	243	394	248	306	363	268	338	552	158	352	340	562	380	346	129	-43	196	-295	-726	538	670	397	366	718	471	698	365	466	316	306	249	301	106	181	93	0	0	77	70	40	111	167	65	69	70	66	2	66
Research Development	10,228	13,605	12,650	13,158	9,870	10,973	11,525	12,620	11,149	20,066	10,091	9,833	13,173	4,800	11,076	13,835	13,292	17,791	11,152	10,631	10,839	11,152	10,504	8,887	8,691	10,807	7,107	7,325	5,462	3,342	2,406	3,324	3,652	4,670	4,330	3,330	3,092	2,433	2,547	1,040	641	527	430	332	3,302	563	803	804	940	743	1,115	804	968	672	970	1,391	2,160	1,720	1,388	1,917	1,093	2,944	3,951	3,709	7,622	6,662	8,259	5,644	4,714	5,014	4,819	4,279	4,523	5,080	4,993	4,404	5,490	4,924	1,178	1,790	3,150	1,968	1,953	1,898	3,610	2,672	4,907	3,338	2,519	1,691	1,733	2,692	1,693	1,955	1,140	1,201	482	1,292	201	339	0
Selling And Marketing Expenses	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Selling General Administrative	50,072	47,759	47,081	50,124	47,473	52,169	51,532	45,197	44,242	44,128	43,786	39,282	38,779	31,068	15,541	11,061	7,246	6,061	4,946	3,901	3,498	2,923	3,462	3,791	3,118	2,650	2,901	3,427	2,227	1,716	1,835	1,192	1,564	1,380	1,414	1,905	1,399	1,405	1,713	2,373	843	495	478	489	4,271	990	974	988	1,640	657	677	729	1,959	755	649	711	2,817	631	1,168	827	3,507	1,096	1,555	1,442	8,673	1,355	1,369	1,663	7,019	1,457	1,699	1,607	7,288	1,860	1,695	2,851	7,120	1,495	2,375	1,704	4,619	2,149	2,527	1,305	2,883	1,012	1,853	999	3,612	2,366	685	637	702	1,417	338	467	345	0	201	203	265
Tax Provision	459	298	-642	436	855	954	9	10	726	8	18	8	157	-35	22	-236	90	25	16	13	73	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Operating Expenses	60,300	64,009	56,101	63,572	55,173	62,831	62,581	59,251	55,628	64,766	53,446	49,638	52,339	36,370	27,110	25,299	20,929	24,241	16,483	14,915	14,692	14,483	14,369	13,077	12,170	13,819	10,378	11,115	8,054	5,420	4,606	4,903	5,579	6,484	6,107	5,633	4,901	4,211	4,629	3,782	2,059	1,102	986	903	5,724	1,769	1,988	2,006	1,979	1,631	2,043	1,776	2,389	1,655	2,022	2,350	3,307	2,663	2,702	3,237	1,699	4,662	5,899	5,495	9,372	8,424	10,030	7,681	6,588	7,035	7,001	6,255	8,426	7,431	7,167	7,640	8,966	6,939	4,246	3,876	5,928	4,446	4,763	3,451	3,276	2,261	2,926	4,430	0	0	2,496	3,398	2,435	2,697	1,663	1,735	896	965	67	543	331
Total Other Income Expense Net	-5,816	3,114	4,036	3,814	2,909	1,464	483	262	-109	106	142	-1,771	-5,743	2,173	-2,665	7,633	-55,949	4,372	-95	1,670	143	-4,925	-1,999	-2,671	8,807	271	7,231	-40,932	-315	-2,036	1,271	572	1,577	1,262	5,306	-3,041	-95	1,614	529	-1,448	-909	-1,327	-17	62	507	-12	-393	-4,207	-4,463	3,267	6,781	-1,185	-327	-98	-10	14	101	64	2,108	-6	-12	254	237	9	523	744	442	400	1,426	-4	-168	-15	140	415	442	457	434	-878	268	518	-449	-855	-864	-1,049	-4,238	2,063	3,562	21	0	0	4	7	1	-17	0	0	69	0	134	68	133
Total Revenue	45,095	54,515	41,494	34,409	28,435	55,779	28,191	21,625	23,404	14,667	6,620	914	50,030	29	29	30	29	230	29	30	29	375	29	30	31	29	329	31	30	31	55	57	57	57	59	62	68	72	71	67	693	84	83	87	86	87	88	5,813	120	535	153	138	298	264	1,414	1,448	1,656	960	618	647	93	2,703	555	563	616	554	429	606	638	519	937	1,369	-1,131	1,763	204	317	255	262	255	468	616	307	6,529	216	300	4,189	5,457	2,203	3,215	256	523	522	448	299	249	67	276	488	201	271	398

Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue	175,513
Cost of Revenue	-14,148
Gross Profit	161,365	161,365

Operating Income (+$)
Gross Profit	161,365
Operating Expense	-244,677
Operating Income	-83,312	-83,312

Operating Expense (+$)
Research Development	49,641
Selling General Administrative	195,036
Selling And Marketing Expenses	0
Operating Expense	244,677	244,677

Net Interest Income (+$)
Interest Income	15,338
Interest Expense	-2,775
Other Finance Cost	-1,310
Net Interest Income	13,873

Pretax Income (+$)
Operating Income	-83,312
Net Interest Income	13,873
Other Non-Operating Income Expenses	0
Income Before Tax (EBT)	-77,469	-89,155 EBIT - interestExpense = -86,087 -77,469 -75,245
Interest Expense	2,775
Earnings Before Interest and Taxes (EBIT)	-83,312	-74,694
Earnings Before Interest and Taxes (EBITDA)	-71,665

After tax Income (+$)
Income Before Tax	-77,469
Tax Provision	-947
Net Income From Continuing Ops	-77,191	-78,416
Net Income	-78,020
Net Income Applicable To Common Shares	0

Non-recurring Events
Discontinued Operations	0
Extraordinary Items	0
Effect of Accounting Charges	0
Other Items	0
Non Recurring	0
Other Operating Expenses	258,825
Total Other Income/Expenses Net	5,843	-13,873

Technical Analysis of Aurinia Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Aurinia Pharmaceuticals Inc. The general trend of Aurinia Pharmaceuticals Inc is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Aurinia Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitions	Bullish trend (-85.7%)		Bearish trend (85.7%)
Overbought to neutral	Bullish pullback	=	Bearish reversal
Upper to lower neutral	Bullish correction	=	Bearish continuation
Nuetral to oversold	Oversold	=	Oversold
Oversold to neutral	Bullish reversal	=	Bearish correction
Lower to upper neutral	Bullish continuation	=	Bearish pullback
Nuetral to overbought	Overbought	=	Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.

Score

Let's take a look at the Support & Resistance of Aurinia Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 5.35 < 5.41 < 6.9401.

The bearish price targets are: 4.07.

Tweet this

Aurinia Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

Moving averages are lagging trend indicators.
There are many types of moving averages.
Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Aurinia Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

MA 20 trending up: The MA 20 is trending up. +1
Close < MA 20: The price is below the MA 20. -1
MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
MA 50 trending down: The MA 50 is trending down. -1
Close < MA 50: The price is below the MA 50. -1
MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
MA 100 trending down: The MA 100 is trending down. -1
Close < MA 100: The price is below the MA 100. -1
MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
MA 200 trending down: The MA 200 is trending down. -1
Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving Average	Amount of candles	vs. MA 50	vs. MA 100	vs. MA 200
MA 20	20
MA 50	50	-
MA 100	100	-	-
MA 200	200	-	-	-

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Shows the moving average of the selected period.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

There are various kinds of moving averages:

Simple moving average (SMA);
Exponential moving average (EMA);
Smoothed moving average (SMMA);
Linear weighted moving average (LWMA).

The moving average looks at a certain period of time and it calculates the price average. The various types of averages are using various formulas. Don’t worry, you don’t have to memorize any formula. All moving averages are calculated automatically by basically every charting software you use. But it’s good to know how moving averages are actually calculated.

Simple moving average

SMA is calculated by summing up the price closures of the selected period. The price is then divided by the selected period. For example, when using the 21 day moving average you sum up all the closing prices for each day and divide that by 21. The result is a line on the chart representing the average. Because it’s an average in the selected timeframe, the trend is always lagging. An moving average looks like this on the chart:

Source: Tradingview.com

In this case, the blue line represents a 21 day moving average. Because the average is based on results from the past, the indicator will always lag behind. For example, when price would suddenly go up, the moving average won't immediately follow.

All other moving averages discussed below look the same on the chart. The only difference is that the line will move in different directions based on the maths behind the used indicators and the amount of days used to determine the average.

Exponential moving average

The EMA gives more weight to the latest closing prices by giving them more value in the equation. EMA is calculated by adding a certain percentage to the latest closing prices:

EMA = (CLOSE (i) * P) + (EMA (i - 1) * (1 - P))

Where:

CLOSE (i) = current period close price.
EMA (i - 1) = value of the Moving Average of a preceding period.
P = the percentage of using the price value.

Smoothed moving average

A smoothed moving average is an exponential moving average with a long lookback period. Older prices are reduced in weight but are never left out in the calculation. Unlike SMA and EMA where prices are removed when they are beyond the selected period. SMMA is a combination of the SMA and EMA. The main advantage is that it smooths out fluctuations in price.

Linear weighted moving average

The LWMA gives the latest price the highest weight and then lineary scales down with each price before that. The result is that the LWMA reacts quicker to changes in price than the SMA or EMA. The formula:

LWMA = ((Pn∗W1)+(Pn−1∗W2)+(Pn−2∗W3)...) / ∑W

Where:

P = Price for the period.
n = The most recent period, n-1 is the prior period, and n-2 is two periods prior.
W = The assigned weight to each period, with the highest weight going first and then descending linearly based on the number of periods being used.

Moving averages are widely used by many traders. Which moving average you need depends on your trading strategy. Common practise is using a combination of multiple periods. For example, the EMA21, EMA50, EMA100 and EMA200. How does that look on a chart:

Source: Tradingview.com

The lowest (purple) line on the chart represents the EMA200 then following up the EMA100, EMA50 and EMA21.

You can use moving averages to determine a trend. The 200 moving average is mostly used as a baseline for determining the current trend:

When the 200 moving average is moving up it is considered a bullish trend.
When the 200 moving average is down it is considered a bearish trend.
When moving averages are flatlined, there is no clear trend so you should look for market structure, consolidation or trend reversals. Depending on how you want to trade.

This is not set in stone. Most trading strategies use multiple moving averages each with different settings. While one strategy might use the EMA20, the other uses the SMA21. There can be hundreds of different variations. Moving averages can also be used as support and resistance. More often than not, prices will bounce on moving averages.

Aurinia Pharmaceuticals Inc Daily Moving Averages Chart

2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

MACD is a lagging momentum indicator.
Uses two moving averages.
Can show buy or sell signals based on momentum.
Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Aurinia Pharmaceuticals Inc. The current macd is -0.13035098.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Aurinia Pharmaceuticals Inc price going up in the near term. +2
MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Aurinia Pharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Aurinia Pharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1

Aurinia Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart

2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.

Score

Let's take a look at the Directional Movement Index (DMI) of Aurinia Pharmaceuticals Inc. The current adx is 18.64.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Aurinia Pharmaceuticals Inc shares, leading to potential upward momentum in its price. +1
PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.

Aurinia Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart

2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

Parabolic SAR (stop and reverse) is a lagging trend indicator.
Shows the current trend.
Shows potential entry signals.
Shows potential exit signals.
Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Aurinia Pharmaceuticals Inc. The current sar is 5.23416362.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1

Aurinia Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

Leading momentum indicator, meaning the signals are instant.
Ranges between 0 and 100.
Above 70 is considered overbought.
Below 30 is considered oversold.
Above or below 50 can also be used to determine price trend or support and resistance.
RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Aurinia Pharmaceuticals Inc. The current rsi is 44.47. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
Trending down: The RSI is trending down. -1

Measures the speed and change of price movements.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

The RSI measures the magnitude of recent price changes to determine if the asset is overbought or oversold.

Overbought (RSI above 70) means that the trading price is above its intrinsic value. This might indicate a sell or short signal.
Oversold (RSI below 30) means that the trading price is below its intrinsic value. This might indicate a buy or long signal.
RSI levels above or below 50 can also be used to determine a trend.
RSI divergence looks at a deviation between RSI and price movement.
Can be used in many different ways.

Original usage

Keep in mind that almost every indicator can be used in different ways. Even beyond the orginal settings. The relative strength index was developed by J. Welles Wilder. Wilder recommended a smoothing period of 14 days. That means a 14 day moving average (read more about this setting below). Another quote from the wikipedia page:

Wilders also considers the RSI 50 line as both support and resistance. I recommend to always read the original settings first before using an indicator. Many traders and websites are using their own version of the indicator which might be confusing.

How you can use RSI (Divergence)

First and foremost, there is no real right or wrong usage of the RSI indicator. You can use it in any way you want. Wilder recommends using a 14 day average but you can make it 50 or 100 if you like. Just keep in mind that using an indicator is just part of a larger trading plan. In other words, it’s not recommended to do any trading or investing based on a single indicator like the RSI.

The RSI is measured on a scale between 0 and 100. From 30 till 0 is considered oversold. and from 70 -100 is overbought. The RSI is a leading indicator, meaning the signals are instant.

I like to use the RSI as a trend\momentum indicator and not as an overbought or oversold indicator. I use the middle (50) as the baseline. When prices go above RSI 50 the trend is bullish and can indicate long positions. When below 50 it is considered bearish and can indicate short positions. Other traders use the 70 and 30 levels as overbought/oversold depending on the used strategy. The RSI indicator looks like this:

Source: Tradingview.com

The general concensus is that an RSI above 70 indicates that the security is overbought. In other words, the price this security is trading for is to high and should come down. So if RSI hits 70 or above this might indicate a sell signal or taking a short position (expecting the price will go down). Although RSI above 70 indicates the security is trading above it's fair value, that does not mean the price will go down.

Use tradingview to add indicators

I highly recommend using tradingview to add indicators to a chart. It has all the indicators you can think off and can add them for free (up to three indicators) to any chart you want. You can see that the levels 30 and 70 are marked with a dotted line. If you want you can remove these lines or give it another colour using Tradingview. You can also adjust the moving average used. You can also find RSI indicators made by the community that include other settings like RSI divergences.

Tradingview

Use Tradingview to (back)test your strategies and add hundreds of indicators created by the community.

View tool on Tradingview.com

RSI divergence

RSI is not only used to determine momentum but can also spot reversals or continuations of the trend. A reversal means that the trend is going in the opposite direction. From bullish to bearish or from bearish to bullish. These reversals can be spotted by looking at the price and the direction of the RSI. When the price is going up but the RSI is going down that means there is a divergence. This is also the case when RSI goes up but price is going down.

There are four types of divergences:

Regular bullish divergence
Regular bearish divergence
Hidden bullish divergence
Hidden bearish divergence

Regular bullish divergence

With a regular bullish divergence, the price is making lower highs but the oscillator (in this case the RSI) is making higher lows. A regular bullish divergence might indicate the end of the current trend. You’ll see regular bullish divergences mostly at the end of a downtrend. But that does not mean that every regular bullish divergence is a trend reversal.

Price is making lower highs
RSI is making higher lows
Indicating bullish reversal (price might go up)

Source: Tradingview.com

Regular bearish divergence

With a regular bearish divergence the price is making higher highs but the oscillator (in this case the RSI) is making lower highs. This might indicate the end of an uptrend.

Price is making higher highs
RSI is making lower highs
Indicating bearish reversal

Source: Tradingview.com

Hidden bullish divergence

With a hidden bullish divergence, the price is making a higher low while the RSI is making a lower low. This might indicate bullish trend continuation.

Price is making higher lows
RSI is making lower lows
Indicating bullish continuation

Source: Tradingview.com

As you have noticed, you can have multiple divergences in a row.

Hidden bearish divergence

With a hidden bearish divergence, price is making lower highs but RSI is making higher highs. This might indicate bearish trend continuation.

Price is making lower highs
RSI making higher highs
Indicating bearish continuation

Source: Tradingview.com

You can find many cheatsheets of RSI divergences online. Search for "RSI divergence overview" and you'll find a lot of examples. You can print these to learn the various types of divergences.

Aurinia Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart

3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

Leading momentum indicator, meaning the signals are instant.
Used to determine overbought and oversold areas much like the RSI.
Ranges between 0 and 100.
Above 80 is considered overbought.
Below 20 is considered oversold.
Consists of two lines named K and D.
K compares the highest high and lowest low on the selected price range.
The D line is a moving average of the K line.
Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Aurinia Pharmaceuticals Inc. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Aurinia Pharmaceuticals Inc price going down in the near term. -2
Trending down: The STOCH %K is trending down. -1

Aurinia Pharmaceuticals Inc Daily Stochastic Oscillator Chart

3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

Lagging or leading Momentum indicator
When the CCI is above zero, the price is above the historical average
When the CCI is below zero, the price is below the historical average
Used for spotting trends
- If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
- If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Aurinia Pharmaceuticals Inc. The current cci is 14.65.

Aurinia Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart

3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

Lagging momentum indicator
Ranges between +100 and -100
Considered overbought above +50
Considered oversold below -50
It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Aurinia Pharmaceuticals Inc. The current cmo is -3.15399745.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1

Aurinia Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart

3.5 Williams %R

Shows the current price relative to the highest high over the last 14 days.

Lagging momentum indicator
Ranging between 0 and -100
Above -20 is considered overbought
Below -80 is considered oversold
Is prone to give false signals

Score

Let's take a look at the Williams %R of Aurinia Pharmaceuticals Inc. The current willr is -41.81818182.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Aurinia Pharmaceuticals Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.

Aurinia Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

Lagging volatility indicator
Uses 3 bands: one upper, one lower and one in the middle
Works best when the middle band reflects an intermediate trend (MA20).
When the price is moving closer to the upper band, the market might be overbought
When the price is moving closer to the lower band, the market might be oversold

Score

Let's take a look at the Bollinger Bands of Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc Daily Bollinger Bands Chart

4.2 Average True Range (ATR)

Measures market volatility

Leading volatility indicator
Can be used to determine stop-loss positions
Calculated by:
- Current high minus the current low
- Current high minus the previous close
- Current low minus the previous close
The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Aurinia Pharmaceuticals Inc. The current atr is 0.19714349.

Aurinia Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Measures market volatility

Leading momentum indicator
Calculation:
- If the closing price is above the previous closing price: OBV = previous OBV + current volume
- If the closing price is below the previous closing price: OBV = previous OBV - current volume
- If the closing price is the same as the previous closing price than the OBV is the same.
Can be used to confirm price trends
Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Aurinia Pharmaceuticals Inc. The current obv is -56,766.

Aurinia Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart

5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

Lagging momentum indicator
Looks like RSI but uses volume as an extra metric (RSI only considers price)
Above 80 is considered overbought
Below 20 is considered oversold
Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Aurinia Pharmaceuticals Inc. The current mfi is 52.27.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

MFI > 50: +1

Aurinia Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

Type	Notification	Date
Currently no notifications for Aurinia Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

Date	Indicator	Signal
2023-12-01	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2023-12-04	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-06	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2023-12-07	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-11	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2023-12-13	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2023-12-15	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
2023-12-18	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-19	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
2023-12-20	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2023-12-21	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2023-12-22	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2023-12-28	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-29	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-01-02	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-03	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-01-04	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
2024-01-05	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-08	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-01-10	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-01-11	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-01-16	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-23	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-24	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-01-25	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-30	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-01-31	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-02-01	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-05	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-02-06	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-09	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-02-13	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-02-15	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-02-21	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-22	RSI	LONG ENTRY	SHORT CLOSE	30 crossover to upside
2024-02-23	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-02-28	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-03-04	MFI	SHORT ENTRY	LONG CLOSE	20 crossover to downside
2024-03-05	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-06	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	MFI	LONG ENTRY	SHORT CLOSE	20 crossover to upside
2024-03-07	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-03-11	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
2024-03-12	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-03-13	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-14	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
2024-03-18	STOCH	LONG EXIT		The %K line crosses below the %D line.
	MFI	SHORT ENTRY	LONG CLOSE	20 crossover to downside
2024-03-19	RSI	LONG ENTRY	SHORT CLOSE	30 crossover to upside
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-20	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	MFI	LONG ENTRY	SHORT CLOSE	20 crossover to upside
2024-03-21	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-22	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-03-25	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-26	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-27	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-28	RSI	LONG ENTRY	SHORT CLOSE	30 crossover to upside
2024-04-01	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-04-02	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-04-09	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-10	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-04-11	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-15	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-04-16	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
2024-04-17	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-04-18	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-04-23	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-04-24	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside

6.3. Candlestick Patterns

Aurinia Pharmaceuticals Inc Daily Candlestick Chart

Date	Candlestick Pattern

6.4. Technical Score

Let's check the technical score of Aurinia Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Rsi	Greater than	50	44.473
Ma 20	Greater than	Ma 50	5.050
Ma 50	Greater than	Ma 100	5.408
Ma 100	Greater than	Ma 200	6.940
Open	Greater than	Close	5.090
Total			1/5 (20.0%)

Create your own Symbol Scanner

Get notifications about Aurinia Pharmaceuticals Inc

I send you an email if I find something interesting about Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc Buy, Hold or Sell?

Let's analyse Aurinia Pharmaceuticals Inc together

Get notifications about Aurinia Pharmaceuticals Inc

Quick analysis of Aurinia Pharmaceuticals Inc (30 sec.)

What can you expect buying and holding a share of Aurinia Pharmaceuticals Inc? (30 sec.)

How much money do you get?

What is your share worth?

+ What do you gain per year?

For what price can you sell your share?

1. Valuation of Aurinia Pharmaceuticals Inc (5 min.)

$5.03

$2.61

$-3.06 - $2.00

$-0.45 - $4.61

2. Growth of Aurinia Pharmaceuticals Inc (5 min.)

Is Aurinia Pharmaceuticals Inc growing?

How much money is Aurinia Pharmaceuticals Inc making?

How much money comes from the company's main activities?

3. Financial Health of Aurinia Pharmaceuticals Inc (5 min.)

4. Comparing to competitors in the Biotechnology industry (5 min.)

Industry Rankings (Biotechnology)

What can you expect buying and holding a share of Aurinia Pharmaceuticals Inc? (5 min.)

What can you expect buying and holding a share of Aurinia Pharmaceuticals Inc?

Speculation

Investing

How much money are you going to get?

When do you get the money?

How sure are you?

Linear %

Fundamentals of Aurinia Pharmaceuticals Inc

About Aurinia Pharmaceuticals Inc

Financial Health

Valuation

1.1. Profitability of Aurinia Pharmaceuticals Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Trends

Compared to industry (Biotechnology)

1.1.2. Return on Assets

Trends

Compared to industry (Biotechnology)

1.1.3. Return on Equity

Trends

Compared to industry (Biotechnology)

1.2. Operating Efficiency of Aurinia Pharmaceuticals Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Trends

Compared to industry (Biotechnology)

1.2.2. Operating Ratio

Trends

Compared to industry (Biotechnology)

1.3. Liquidity of Aurinia Pharmaceuticals Inc.

1.3. Liquidity

1.3.1. Current Ratio

Trends

Compared to industry (Biotechnology)

1.3.2. Quick Ratio

Trends

Compared to industry (Biotechnology)

1.4. Solvency of Aurinia Pharmaceuticals Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Trends

Compared to industry (Biotechnology)

1.4.2. Debt to Equity Ratio

Trends

Compared to industry (Biotechnology)

2. Market Valuation of Aurinia Pharmaceuticals Inc

2.1. Earnings Per Share

2.1. Price to Earnings Ratio

Trends

Compared to industry (Biotechnology)

Aurinia Pharmaceuticals Inc
Buy, Hold or Sell?